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ABSTRACT 
 
The roles of dietary polyphenols, such as resveratrol found in red wine and grape seed 
extract, have become an increasingly more popular research topic. Dietary polyphenols 
have even achieved media success for their potential benefits on human health and 
disease. The success is frequently attributed to the compounds’ antioxidant and reactive 
oxygen species (ROS) scavenging abilities. Not only are polyphenols highlighted as the 
benefitial health constituents of herbal remedies, but there are also two plant-polyphenol 
drugs approved by the United States Food and Drug Administration, Crofelemer (a 
proanthocyanidin oligomer from Croton lechleri) and Veregen (catechins from 
Camellia sinensis). Due to the demand for novel polyphenolic lead compounds, three 
major classes were chosen to be explored as part of this dissertation: stilbenes, 
gallotannins, and ellagitannins. The investigation of stilbenes includes an invited 
literature update on novel natural stilbenes, which have been isolated and identified 
since 2009.  The review concludes by discussing the biological activities and potential 
health benefits of this polyphenol sub-class. Additionally, two new monomeric 
stilbenes, namely, vulpinoideols A and B, along with ten known compounds were 
isolated from a fox sedge (Carex vulpinoidea) acetone seed extract. All of the isolates 
were evaluated for their tyrosinase enzyme inhibitory activity, along with the well-
known competitive inhibitor, arbutin. A synthetic route for naturally isolated 
gallotannins, namely, maplexins F and J, previously isolated from red maple (Acer 
rubrum) tree bark, was developed.  Additionally, the ligand-enzyme interaction between 
the gallotannins and their target enzyme, α-glucosidase, was evaluated using 
iii 
 
biophsyical tools including isothermal titration calorimetry (ITC), fluorescence, and 
circular dichroism (CD) spectroscopic methods. Finally, a synthetic route was also 
developed for the ellagitannin gut-microbial metabolites, urolithins (dibenzopyranone 
derivatives), along with analytical UFLC-MS/MS methods to study the cellular and 
tissue uptake of the urolithins, as well as other dietary polyphenolic metabolites of 
interest. 
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STATEMENT OF THE PROBLEMS 
 
Natural products continue to provide an inspiration for new drug targets and synthetic 
scaffolds.  Between 1940 and 2010, a total of 175 small-molecule, anti-cancer 
therapeutics have been approved by the Food and Drug Administration.  Of those 175 
approved therapies, 49% were either discovered or derived directly from a natural 
product [1]. Even with natural products providing such a large influence towards the 
generation of new pharmaceuticals, there is still a growing demand for the discovery 
of new lead compounds.  This demand puts continuous pressure on finding novel 
compounds, and sources, for drug candidates.     
 
The polyphenols of interest are secondary metabolites, and are not directly responsible 
for the growth and development of the producing organism.  As a result, these 
compounds are frequently isolated in low yields from their natural sources.  Obtaining 
the natural biomass can be economically and scientifically impractical (e.g. deep ocean 
bacteria or the bark of a tree).  Therefore, to investigate a natural product isolate as a 
potential drug candidate, a synthetic route must often be developed.  
 
Over the past decade, the fate of dietary polyphenols upon ingestion has continued to 
attract increased research attention.  Several sub-classes of polyphenols are poorly 
bioavailable in their intact forms, but are extensively metabolized by gut-microflora. 
This results in the hydrolysis of sugar substituents, alkylation of vulnerable oxygen and 
nitrogen functional groups, and a series of oxidation-reduction reactions.  The final 
metabolite of dietary polyphenols often has a completely different chemical structure 
 2 
 
and set of properties from what was originally consumed. As these metabolized 
polyphenols are, in fact, the biologically available metabolic endproducts, it is 
imperative to develop analytical methods for evaluating the potential impact of these 
compounds.  
 
[1] G. M. Cragg and D. J. J. Nat. Prod. 2012, 60, 52-60. 
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CHAPTER 1 
STILBENES 
 
Manuscript 1 appears as published:  
 
Invited Review: Beyond Resveratrol: A Review of Natural Stilbenoids Identified from 
2009-2013. Niesen, Daniel B.; Hessler, Craig; Seeram, Navindra P. (2013) Journal of 
Berry Research. 4, 181-196…………………………………………………….……..8 
 
Manuscript 2 appears as published:  
 
Phenolic Constituents of Carex vulpinoidea Seeds and their Tyrosinase Inhibitory 
Activities. Niesen, Daniel B.; Ma, Hang; Yuan, Tao; Bach, Alvin C. II; Henry, Geneive 
E.; Seeram, Navindra P. (2015). Natural Product Communications. 10, 491-493…..38 
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ABSTRACT 
Natural stilbenes have become an increasingly popular research topic of many natural 
product groups throughout the world, due to their elaborate structures and dynamic 
biological activities. Stilbenes are phenolic compounds, and are an exciting class that 
have been found in 33 plant families. Even though their carbon monomeric form is a 
simple 1,2-diphenylethylene unit, stilbenes display a wide variety of polymerization 
and oligomer construction [1].  They most commonly refer to the compounds that are 
hydroxylated derivatives of the stilbene carbon backbone.  Stilbenes have been isolated 
in monomeric forms, like resveratrol, oligomer forms, such as α-viniferin, and 
glycosides like astringin [1].   
 
Stilbenes are produced as a woody metabolite, and may serve as constitutive and 
inductive defense agents. The antimicrobial activity of plant stilbenes, and the fact that 
they are both constitutive and inducible, strongly suggests that their concentrations are 
a good indication of their role in disease resistance [1].  Because of this, stilbenes have 
been the focus of a variety of research topics for their potential benefits.  
 
Resveratrol has been extensively studied due to its wide range of biological activities 
and occurrence in plant foods, including grape and some berries. Apart from the intact 
resveratrol molecule and closely related analogs, this compound can be regarded as a 
monomer which occurs as a primary building block for subsequent polymerization, 
which leads to the extensive structural diversity within the chemical classification.  
 5 
 
Stilbenoids exhibit a vast array of polymerization and oligomeric construction, with 
over 60 such naturally occurring stilbenes being isolated and identiﬁed in the last ﬁve 
years alone, adding to the hundreds which are already known to date (Manuscript 1).  
 
The Carex genus (family, Cyperaceae) contains over 2000 species [2], but the majority 
of these remain largely uninvestigated for their phytochemical constituents. This is 
unfortunate, considering that the Cyperaceae family is one of the few plant families 
known to produce stilbenoid derivatives [3, 4]. Previously, our group has studied Carex 
species found in the northern regions of the United States, which has yielded several 
bioactive phenolic constituents, including resveratrol oligomers and other stilbenoids 
[5, 6]. 
 
Hyperpigmentary disorders, such as melasma and freckles, are due to the abnormal 
accumulation of melanin.  The tyrosinase enzyme has been implicated as a key enzyme 
in melanogenesis, as it initiates an enzymatic cascade through the conversion of 
tyrosine and 3, 4-dihydroxyphenylalanine (L-DOPA) into DOPA-quinone [7, 8].  
Notably, plant natural products, in particular, phenolic compounds, have shown great 
promise as tyrosinase inhibitors, a primary example being the phenolic glycoside, 
arbutin, which is widely used for commercial cosmetic applications [9, 10]. Moreover, 
several phenolic sub-classes, including flavonoids, chalcones, and stilbenoids, are 
known to be tyrosinase inhibitors [11-13].  
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In the pursuit to of novel stilbenoids, the seeds of the previously uninvestigated Carex 
vulpinoidea Michx were investigated for their phytochemical composition.  The 
isolates were also evaluated for their anti-tyrosinase activities. The approach involved 
isolation and structural elucidation of phytochemicals by using various 
chromatographic separation techniques and analytical approaches including NMR 
(nuclear magnetic resonance) spectroscopy and MS (mass spectrometry).   
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Abstract  
Polyphenols constitute a large chemical class of phytochemicals among which the 
stilbenoid sub-class has attracted signiﬁcant attention due to their elaborate structural 
diversity and biological activities.  Resveratrol, a well-known stilbene, has been 
extensively studied due to its wide range of biological activities and occurrence in plant 
foods, including grape and some berries. Apart from the intact resveratrol molecule and 
closely related analogs, this compound can be regarded as a monomer which occurs as 
a primary building block for subsequent polymerization which leads to extensive 
structural diversity.  Consequently, stilbenoids exhibit a vast array of polymerization 
and oligomeric construction, with over 60 such naturally occurring stilbenes being 
isolated and identiﬁed in the last ﬁve years alone, adding to the hundreds which are 
already known to date. This review updates the literature on natural stilbenoids which 
have been isolated and identiﬁed since 2009 and discusses the biological activities of 
this sub-class of bioactive polyphenols as a whole. 
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1.0 Introduction 
1.1. Stilbenes 
Over the past few decades, signiﬁcant research attention has been directed towards the 
investigation of polyphenols, a large class of secondary metabolites which are abundant 
in plants and plant-derived foods including grapes, and some berries and nuts. Within 
the large chemical class of (poly)phenolic compounds, the stilbenoids, which occur in  
33 plant families, have been extensively studied both as pure compounds and enriched 
plant derived extracts [1, 2]. Consequently, their potential applications either as 
botanical supplements or as active constituents in medicinal and cosmetic preparations 
have been evaluated [1].  Notably, stilbenoids have been isolated and studied as 
monomers and oligomers, as well as glycosylated derivatives with the best known 
example being resveratrol as well as others including α-viniferin, and astringin (see 
Fig. 1) [2]. The carbon skeleton of stilbenes occurs as a C6–C2–C6 unit, namely, a 1, 
2-diphenylethylene moiety, however, the commonly hydroxylated derivatives provide 
the class with a wide variety of polymerization and oligomeric construction. Stilbenes 
are produced by plants as a woody metabolite, as well as constitutive and inductive 
defense agents.  The antimicrobial activity of plant stilbenes, and the nature of these 
compounds as being both constitutive and inducible secondary metabolites, suggests 
that their in situ concentrations are a good indication of disease resistance [2]. 
Historically, signiﬁcant research has focused on the role of stilbenes and their activity 
as anti-bacterial agents, antioxidants, anti-inﬂammatory agents, anticancer and cancer 
chemopreventive agents, and more recently their role in the regulation of several human 
degenerative diseases [3-9]. 
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1.2. Occurrence of resveratrol in berries 
The occurrence of stilbenes in berries has largely been reported for the so called ‘model 
stilbenoid’ compound, namely, resveratrol (Fig. 1) which was originally isolated from 
the roots of Veratrum grandiﬂorum in 1940 [10]. Notably, as mentioned previously, in 
nearly every case highlighted in the current review, resveratrol has been used as the 
primary building block during the polymerization into larger stilbenes.  
 
 
 
Figure 1. Stilbene derivatives highlighting the common monomer, resveratrol (left), a 
trimer α-viniferin (center), and a glycosylated derivative, astringin (right). 
 
 In many grape varieties, trans-resveratrol is a phytoalexin produced to combat the 
growth of fungal pathogens such as Botrytis cinerea, a necrotic fungus whose most 
notable host is wine grapes [11]. Resveratrol’s presence in Vitis vinifera grapes is also 
constitutive, with a natural accumulation in the skin of ripe berries.  In muscadine 
grapes (Vitis rotundifolia), a species native to the southeastern United States, 
resveratrol has been isolated from the seeds as well as the skin [12]. The concentration 
of resveratrol present in grape skins varies with the grape cultivar, its geographic origin, 
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and exposure to infections. As red wine is fermented with the skins, it contains a higher 
concentration of resveratrol as compared to white wines. Depending on the grape 
variety, the concentration of resveratrol in red wines ranges between 0.2–5.8mg/L, with 
a direct correlation in the amount of fermentation time a wine spends in contact with 
the grape skins [13].  
 
Resveratrol has also been detected in several other berry varieties. It has been identiﬁed 
in blueberry, bilberry, cowberry, red currant, cranberry and strawberries; however these 
berries contained less than 10% of that present in grapes [14, 15]. The content of trans-
resveratrol in the fresh weight of the above fruit ranges from 3–30µg/g [15]. 
Additionally, it has been reported that heating and cooking the berries will contribute 
to the degradation of resveratrol [14]. 
 
1.3. Occurrence of resveratrol and other stilbenes in non-berry food sources 
Resveratrol and polymeric stilbenes have been found in other food sources apart from 
the various berry varieties. Interestingly, a source of resveratrol derivatives is peanuts 
(Arachis hypogea), in particular, sprouted peanuts, where the resveratrol content rivals 
that of grape skins. Depending upon peanut cultivar, the resveratrol content ranges from 
2.3–4.5µg/g before sprouting and 11.7–25.7µg/g after sprouting [16]. Two new 
resveratrol dimers were recently isolated from peanut seeds and are discussed later in 
this review [17]. Cocoa powder, baking chocolate, and dark chocolate have also been 
reported to contain small concentrations of resveratrol in normal consumed quantities 
i.e. 0.35–1.85mg/kg [18]. 
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1.4. Previous review articles on stilbenes 
To date, there are several reviews available on the pharmacological beneﬁts of 
resveratrol and its analogs [19–21]. Most recently, in 2009, Shen and co-workers have 
published a comprehensive examination of the novel chemistry related to stilbenes 
discovered over the time period from 1995 to late 2008 [2].  Therefore, in this review, 
we examine new stilbene chemistry that has been reported from 2009 to late 2013, 
bridging the gap in period previously reported by Shen and co-workers [2]. During the 
current period covered herein, over 60 naturally occurring stilbenes have been isolated 
and identiﬁed with structures ranging from glycosylated monomers to a hexamer. 
Current scientiﬁc interest in determining the biological activity of this class of 
compounds will also be highlighted. 
 
2. Stilbenes isolated and identiﬁed since 2009 
2.1. Compound classiﬁcation 
While more complex classiﬁcation systems for stilbenes have been proposed by 
Sootheeswaran and Pasupathy [22], for the purpose of this review, the novel chemistry 
isolated has been grouped into: monomers, dimers, trimers, tetramers, and hexamer 
units. Additionally there was one norstilbene isolated, as well as stilbenes containing 
glycoside moieties, which we have differentiated based on their carbon-carbon or 
carbon-oxygen connectivity. These compounds are discussed below. 
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2.2. Stilbene monomers 
Only two stilbene monomer derivatives were isolated during this time period. While 
the stilbene structure provides a large variety in the ways of polymerization, the 
diphenylethylene unit does not have many locations for potential modiﬁcations into 
novel monomers. Although the discovery of new monomers is less common, two 
prenylated derivatives were successfully isolated and identiﬁed. From black skin 
peanut seeds challenged with the fungal strain Rhizopus oligoporus, Liu et al. [23] 
isolated the methoxy-prenylated derivative shown in Fig. 2 (compound shown on left).  
Shan and co-workers [24] successfully isolated the additional monomer, cudrastilbene, 
from the roots of Cudrania tricuspidata, an ethnobotanical plant used commonly in 
China, Korea, and Japan for medicinal purposes. The two new compounds can be found 
in figure 2. 
 
Figure 2. 3,5,3’-trihydroxy-4’-methoxy-5’-isopentenylstilbene (left) and cudrastilbene 
(right) isolated from fungal challenged black skin peanut seeds and Cudrania 
tricuspidata respectively.  
 
2.3. Stilbene dimers 
During the time period of this review, a total of 17 dimeric stilbenes were reported.  
Among the oligomeric stilbenes, the resveratrol monomer is most commonly used for 
construction. There are many combinations of C–C and C–O bonding patterns that can 
arise during the polymerization of the resveratrol units. However, the most common is 
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the formation of the benzofuran moiety. This is apparent, as it is seen in almost all of 
the newly isolated stilbene dimers. 
 
Arguably, most structurally unique of the dimers are the two phytoalexins isolated by 
Sobolev et al. [17]. Interestingly, the production of these two compounds was induced 
by subjecting peanut seeds (Arachis hypogaea) to fungal (Aspergillus caelatus) 
infection. Isolation and puriﬁcation of the fungal challenged seed’s chemical 
constituents resulted in the discovery of two new prenylated dimers of resveratrol, 
arahypin 6 and 7 (Fig. 3). 
 
Figure 3. Arahypin 6 (left) and arahypin 7 (right) isolated from peanuts (Arachis 
hypogaea). 
 
Plants of the genus Gnetum have previously been reported to be rich sources of 
oligomeric stilbene derivatives [25]. Similarly, in the current time period of 2009–
2013, for this review, this was also true with the isolation and characterization of 
macrostachyols C and D from the roots of Gnetum macrostachyum (Fig. 4) [25]. 
Interestingly, macrostachyol C does not contain a benzofuran moiety as observed in the 
majority of the stilbene dimers.  
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The genus Shorea had previously been reported to contain stilbenoids, although the 
work done by Patcharamun and co-workers in 2011 was the ﬁrst phytochemical 
investigation conducted on Shorea ruxburghii [26], a medicinal plant used in India. 
This work resulted in the isolation of roxburghiol A (Fig. 5).  
 
 
 
Figure 4. Macrostachyols C (left) and macrostachyol D (right) isolated from Gnetum  
macrostachyum. 
 
 
 
Figure 5. Roxburghiol A isolated from Shorea roxburghii. 
 
Vaterioside A (Fig. 6), was isolated from the leaves of Vateria indica by Ito et al. [27]. 
Previously, studies have shown that this carbon skeleton can be produced by exposing 
ε-viniferin to photo-oxidative conditions [28].  However, this is the ﬁrst chemical 
isolation from natural sources.  A glycosylated form of vaterioside A was additionally 
isolated during this phytochemical investigation (compound is shown in Fig. 22).  
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Four new dimers were reported from the stem wood of Hopea hainanensis by Ge et al. 
[29]. This group has previously isolated, and characterized, several other stilbene 
oligomers from the Hopea genus.  This recent work resulted in the isolation and 
characterization of four new structures, each of which has notable differences (Fig.7). 
Hopeahainol C is more unsaturated when compared to the other dimers of this review, 
lacking a single sp3 hybridized carbon. The relatively stereochemistry of these 
compounds were unambiguously determined using NOESY experiments [29].  
 
 
Figure 6. Aglycone of vaterioside A isolated from Vateria indica. 
 
 
Figure 7. Hopeahainols C-F (left to right, top to bottom, respectively) isolated from 
Hopea hainanensis. 
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Examination of the branches and twigs of the tropical plant Vatica mangachapoiby Qin 
et al. [30] afforded the three new dimers shown in Fig. 8. The compounds were isolated 
in a bioassay-guided fractionation targeting compounds with xanthine oxidase (XO) 
and acetylcholinesterase (AChE) inhibitory effects. Interestingly, vaticahainol A shows 
rearrangement from the original resveratrol unit. The structure contains a lactone 
moiety, which is not seen in the other dimers discussed in this review. Vaticahainol B 
contains a quinone ring, which also has not been seen in many other isolated stilbenes. 
The quinone moiety is recognized by four quaternary sp2 C-atoms and two protonated 
sp2 C-atoms, which suggests the presence of a cyclohexa-2,5-dienone system. The ﬁnal 
structure, vaticahainol C, contains a distinctive phenanthrene moiety [30]. 
 
 
 
Figure 8. Vaticahainols A-C (left to right, respectively) isolated from Vatica 
mangachapoi. 
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While studying the stems of Vatica albiramis, Abe et al. [31] isolated several new 
stilbenes oligomers [31]. These include the dimer, albiraminol B, which is nearly 
identical to a previously known compound, malibatol A (Fig. 9). The only difference 
between these two compounds is stereochemistry in the connectivity between the A1 
and A2 rings. Notably, malibatol A was also isolated by this group from the same 
fraction.  
 
Figure 9. Albiraminol B (left) and malibatol A (right) isolated from Vatica albiramis. 
 
Working with the methanol extract of the whole plant Cyperus longus, which is used 
traditionally in Egyptian medicine as a tonic and a diuretic, Morikawa et al. [32], using 
bioassay guided fractionation, were able to identify three stilbenes (Fig. 10) [32]. These 
include longusol A and B which contain similar connectivity using the common 
benzofuran ring to connect the two resveratrol monomers.  The carbon skeleton 
presented by these two structures has been previously reported as opposing 
stereoisomers, as well as re-isolated by this group during the investigation of C. longus. 
Longusol C contains a 1,4-dioxane moiety to connect the resveratrol units, however its 
stereoisomer was also previously reported. The stereoisomer was again re-isolated by 
the group.  
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While working with fungal challenged black skin peanut seeds Liu et al. [23] isolated 
two new prenylated stilbene dimers, arahypin-11 and arahypin-12, along with the 
monomer previously mentioned in Fig. 2. Their isolation of prenylated stilbenes from 
fungal challenged peanut seeds follows previous publications, most notably the 
previously mentioned Sobolev et al. [17]. Arahypin-11 and -12 can be found in Fig. 11.  
 
 
Figure 10. Longusol A-C (left to right, respectively) isolated from Cyperus longus. 
 
 
Figure 11. Arahypin-11 and -12 isolated from fungal challenged black skin peanuts. 
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The last dimer isolated contains an aryl coupling between two benzofuran stilbene 
monomers.  The roots and stems of Vitis amurensis have been used ethnobotanically 
as pain relievers, and in this investigation yielded the isolation of the novel dimer [33]. 
The compound can be found in Fig. 12. 
 
Figure 12. Dimer isolated from the roots and stems of V. amurensis.  The compound 
contains an aryl carbon-carbon linkage of two benzofuran monomers. 
 
2.4. Stilbene trimers 
Of the compounds isolated during this time period, only 4 were stilbene trimers. Three 
of these four compounds were isolated from the plant Paeonia suffruticosa by He et al. 
[34], two of which are a pair of stereoisomers (Fig.13) [34]. The third compound, 
isolated from P. suffruticosa is cis-gnetin H. The three compounds contain the same 
carbon skeleton and the resveratrol monomer units are connected by benzofuran rings. 
The absolute stereochemistry of the three trimers was determined using NOESY NMR 
and circular dichroism [34]. 
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Figure 13. cis/trans-suffruticosol D and cis-gnetin H (left to right, respectively) 
isolated from Paeonia suffruticosa. 
 
As previously mentioned, plants of the genus Gnetum are rich sources of oligomeric 
stilbene derivatives [25]. Along with the isolation of the two dimers, macrostachyol C 
and D, Sri-in et al. isolated a novel trimer from Gnetum macrostachyum, named 
macrostachyol B (Fig. 14) [25]. The structure contains an interesting carbon bridge 
creating the bicyclic internal ring system. 
 
 
Figure 14. Macrostachyol B isolated from Gnetum macrostachyum. 
 
2.5. Stilbene tetramers 
Similarly to the stilbene dimers, the majority of the stilbene tetramers contain a 
benzofuran moiety. This is due to the fact that the tetramers are primarily ‘dimers of 
 23 
 
dimers’. As shown in the current review, as well as the most recent other review 
reported by Shen et al. [2], the diversity of stilbene dimers is quite extensive. Due to 
the number of active functional groups that allow for the ease as well as variety in 
polymerization, once a dimer is formed, there are several positions whereby these 
newly formed dimers can polymerize to form tetramers of resveratrol. This ease in 
polymerization is responsible for the increasing diversity of resveratrol dimers and 
tetramers.  
 
Two new tetramers were isolated from Upuna borneensis, conducted by Ito et al. [35]. 
The group has previously reported a structural variety of resveratrol oligomers from U. 
borneensis, while in this report they were investigating the acetone extract of the plant’s 
stems. Their work afforded the two new tetramers, upunaphenols O and P (Fig. 15) 
[35]. Upunaphenol O consists of the resveratrol dimers ampelopsin A and cis-ε-
viniferin. Additionally both of the dimer-subunits were isolated by the group, whom 
had hypothesized that they are indeed the building blocks of the tetramer [35]. 
Upunaphenol P contains a similar dimer unit to upunaphenol O, however the 
determination of whether it is derived from ampelopsin A or B is inconclusive.  
Additionally, it contains a unique C–C bridge between the two dimer pieces.  
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Figure 15. Upunaphenol O (left) and Upunaphenol P (right) isolated from Upuna 
borneensis 
 
Along with the isolation of the two dimers, macrostachyol C and D, and the trimer 
macrostachyol B, this group also isolated a novel tetramer from Gnetum 
macrostachyum, macrostachyol A (Fig.16) [25].  Macrostachyol A differs from other 
common tetramers, as based on the bonding pattern it does not appear to be a dimer of 
a dimer. Instead, the bonding suggests that macrostachyol A is derived from latifolol, 
a resveratrol trimer, combined with yet another resveratrol unit through oxidative 
coupling [25]. It is noteworthy to add that this group also isolated latifolol, which adds 
credibility of their oxidative coupling hypothesis.  
 
 
Figure 16. Macrostachyol A isolated from Gnetum macrostachyum. 
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The next two resveratrol tetramers return to the commonality of a dimer of dimers and 
include cajyphenol A and B which were isolated from Cayratia japonica by Bao et al. 
[36] (Fig. 17). These two tetramers contains the same carbon skeleton, however differ 
in their attachment of the two dimer sub-pieces. Additionally the southern portion of 
each the two molecules contains opposing relative stereochemistry.  
 
 
Figure 17. Cajyphenol A (left) and cajyphenol B (right) isolated from Cayratia 
japonica. 
 
The ﬁnal resveratrol tetramer isolated during the time of this review, is also the only 
tetramer that displays a carbon-symmetric structure (Fig. 18). Vateriaphenol F was 
isolated from the leaves of Vateria indica by Ito et al. [27]. The dimer of dimers is 
constructed from two ε-viniferin pieces. In this example, the use of the furan moiety 
has been used to polymerize each step of the oligomer from the resveratrol monomers.  
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Figure 18. Vateriaphenol F isolated from Vateria indica. 
2.6. Stilbene hexamer 
There was only one hexamer isolated during the time period covered by this review, 
and it is only the ﬁfth instance of a resveratrol hexamer being isolated from a natural 
source (Fig. 19). This hexamer was isolated from the acetone extract of Vatica 
albiramis stems by Abe et al. [31]. The structure consists of a tetramer, vacticanol A, 
and a dimer unit. Additionally it is important to note the 1,2-aryl shift which occurred 
in resveratrol F has rarely been seen in isolated oligomers [31]. 
 
Figure 19.  Albiraminol A isolated from Vatica albiramis. 
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2.7. Norstilbene 
An interesting structure, longusone A, was isolated from the methanol extract of the 
whole plant Cyperus longus by Morikawa et al. [32] (Fig. 20). When compared to those 
structures in this review, this compound has several unique features.  As stated 
previously, the majority of the stilbene oligomers were constructed using resveratrol as 
the monomeric unit.  However, the building block in this molecule contains an 
additional hydroxyl functional group.  The presence of the hydroxyl group in the ortho 
position on the southern-most di-substituted ring, although uncommon, is not 
improbable as it is present from the portion of resveratrol that is constructed from the 
shikimate biosynthetic pathway. Additionally this compound contains a tropilene 
moiety, in which for the purpose of this review, had not been previously observed in 
natural stilbenes. The author, Morikawa et al. [32], describes this molecule as a 
norstilbene dimer, however it seems unlikely that the molecule’s origin is a true stilbene 
dimer (Fig. 20). 
 
 
Figure 20. Longusone A isolated from Cyperus longus. 
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2.8. O-glycosylated stilbenes 
The previous stilbenes reported in this review have not been glycosylated. During the 
period in which this review covers, there were 13 O-glycosylated structures reported 
of which, four were monomers, six dimers, and three tetramers. Like many other classes 
of compounds, the most common sugar moiety added is glucose and in the case of this 
review, all of the sugar moieties added through O-glycosylation were glucose.  
 
Upon fractionation of the aerial portions of the Mongolian medicinal plant, Scorzonera 
radiata, Wang et al. [37] isolated four new glycosylated monomers (Fig.21) [37].  
These monomers differ from the typical resveratrol monomer with the addition of the 
acetate unit at C1, as well the substitution pattern in ring B. Additionally, several of 
these monomers have methyl modiﬁcations at various locations generating methoxyl 
functional groups. The group also isolated a dimer of Fig. 21’s compound 1, which was 
connected through a C–C bond and the 5ˊ carbon (Fig. 21) [37]. 
 
Figure 21. Four glycosylated monomers and a dimer isolated from Scorzonera 
radiate. 
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Two new glycosylated compounds were isolated in the leaves of Vateria indica by Ito 
et al. [27]. One of the structures, a dimer, is previously mentioned in this review as 
having an aglycone that had previously not been isolated in nature (Fig. 5). The group 
also isolated a tetramer with an aglycone, consistent with that of hopeaphenol, a dimer 
of two ampelopsin units (Fig. 22) [27].   
 
Figure 22. Vaterioside B isolated from Vateria indica. 
 
Two publications from the same group, Abe et al. [31, 38], resulted in the ﬁnal six O-
glycosylated stilbenes isolated in the time frame of this review [31, 38].  All six were 
isolated from the stems of Vatica albiramis and named vatalbinosides A-F (Fig. 23). 
The group isolated 4 dimers and 2 tetramers. While these glycosylated versions are 
newly isolated compounds, each of the compounds respective aglycones are previously 
described skeletons. 
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Figure 23. Vatalbinosides A-F isolated from Vatica albiramis. 
 
 
2.9. C-glycosylated stilbenes 
While O-glycosylated structures are much more common, occasionally C-glycosylated 
structures are also reported among stilbenoids. Abe et al. [39] isolated four new C-
glycosylated structures from Hopea parviﬂora, namely, 2 pentamers, a trimer, and a 
dimer.   These compounds have been named hopeasides A-D (Fig.24).   The two 
pentamers are the ﬁrst C-glucopyranosyl resveratrol oligomers isolated to date. 
Moreover, they are stereoisomers of each other but the orientation in which the two 
differ remains unknown.  The orientation, interestingly, is in regard to the orientation 
of the C–C bonds between 7e-8e-9e. Theoretically, these are sp3 hybridized freely 
rotatable bonds, however due to the steric hindrance within the molecule, rotation is 
restricted creating the two stereoisomers. 
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Figure 24. Hopeasides A-D (left to right) isolated from Hopea parviflora. 
 
3. Biological activity of stilbenoids 
Historically, there has been signiﬁcant work done on the role of stilbenes and their 
activity as anti-bacterial agents, antioxidants, several anticancer properties, NFκB and 
hemeoxygenase moderators. For example, kobophenol-A and -B are tetrastilbenes that 
were ﬁrst isolated from Carex kobomugi and Carex pumila, respectively. These 
compounds have been shown to have moderate inhibitory activity against 
Staphylcoccus aureus [3, 4]. Due to the inherent (poly)phenolic structure of stilbenes, 
there has been extensive research conducted on their role as antioxidants. Reactive 
oxygen species (ROS) are generated in bio-organic redox processes. Deregulation of 
this dynamic biological process leads to oxidative stress, which has been linked to 
many chronic human diseases including cancer, diabetes, and cardiovascular diseases 
[5].The direct efﬁcacy of stilbenes ability for the scavenging of ROS, or induce 
NADPH oxidase and xanthine oxidase inhibition, however still remains unclear [1].  
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An additional biological property that stilbenes exhibit is the inhibition of 
topoisomerase II.  Topoisomerases play a critical role in the unwinding of coiled DNA 
during cellular transcription [6].  Upon discovering this mechanism for oligomeric 
stilbenes, Yamada et al. [6] conducted a study on over 40 stilbenes and their ability to 
inhibit topoisomerase II and identiﬁed α-viniferin as being highly active. In addition to 
its ability to inhibit topoisomerase II, α-viniferin has also been reported to not induce 
apoptosis, but interestingly arresting cell-cycle in the S-phase in human colon 
tumorigenic cells [7].  
 
Resveratrol has also been implicated in the modulation of several proteins involved in 
a variety of degenerative diseases. It has been shown that resveratrol down regulates 
NFκB, an important protein complex involved in cell survival and proliferation. 
Incorrect regulation of NFκB has been linked to cancer, inﬂammatory and autoimmune 
diseases, septic shock, viral infection, and improper immune development [8, 9]. 
Resveratrol has also been linked to moderate hemeoxygenase activity, which catalyzes 
the cleavage of heme to form iron, CO and bilirubin. Incorrect activity within 
hemeoxygenase has been linked to Parkinson’s and Alzheimer’s diseases [8, 9]. 
Finally, resveratrol has been shown to ameloriate some of the problems associated with 
type II diabetes, such as myocardial ischemia [40].  
 
More recently, resveratrol and some of its analogs, have been linked to anti-aging 
properties. It was shown that through mimicking caloric restriction, resveratrol 
prolonged the lifespan of budding yeast, Saccharomyces cerevisiae. Supporting results 
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followed with additional organisms, including the nematode, Caenorhabditis elegans, 
the fruit ﬂy, Drosophila melanogaster, and the honey bee, Apis mellifera [41–44]. With 
mammals, the ﬁrst experiments carried out in mice conﬁrmed that resveratrol mimicked 
the effects of caloric restriction including reduced albumin uria, decreased 
inﬂammation, and apoptosis in the vascular endothelium, increased aortic elasticity, 
greater motor coordination, reduced cataract formation, and preserved bone mineral 
density [45].  
 
Since aging is a complex process, one could anticipate that the role that stilbenes play 
in exerting anti-aging effects could be achieved by targeting multiple physiological 
processes. In fact, resveratrol appears to ﬁt such a hypothesis, although its exact 
mechanism is not yet fully established. The most intriguing observation linking 
resveratrol with longevity was its ability to activate members of the sirtuin (SIRT) 
family, especially SIRT1 [41].  SIRT1 has been shown to mediate the beneﬁcial effects 
of caloric restriction on longevity extension [46]. Resveratrol was also shown to reverse 
a variety of age-related conditions by counteracting mitochondrial dysfunction and 
metabolic diseases [47]. Several of these effects are SIRT1-dependent, but many others 
are mediated through independent pathways, such as a cAMP-PKA-AMPKA cascade 
[48]. 
 
4. Summary and concluding remarks 
In summary, this review covers the chemical structures of natural stilbenoids isolated 
and identiﬁed from 2009–2013. It is apparent that stilbenes are an exciting chemical 
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class of natural polyphenolic compounds with a unique carbon backbone that allows 
them to polymerize into complex structures and to be biologically active in a variety of 
systems. They have been implicated in the inhibition of growth of microbes, as well as 
to be strong anti-oxidants. In addition, this class of compounds has the ability to inhibit 
the growth of cancer cells in vitro. These compounds display great potential in their 
chemical diversity but understanding of their role in human health prevention and 
disease risk reduction would need further studies into their in vivo biological potential 
and mechanisms of action. 
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Abstract 
Two new phenolics, a stilbenoid, vulpinoideol A (1), and a chalcone, vulpinoideol B 
(2), along with ten known compounds (3-12) were isolated from Carex vulpinoidea 
seeds.  The structures of compounds 1-12 were elucidated based on spectrometric and 
spectroscopic analyses including HRESIMS, 1D and 2D NMR data. All compounds 
were evaluated for their tyrosinase enzyme inhibitory activities. 
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1. Introduction 
 
The Carex genus (family, Cyperaceae) contains over 2000 species [1], but the majority 
of these remain largely uninvestigated for their phytochemical constituents. This is 
unfortunate, considering that the Cyperaceae family is one of the few plant families 
known to produce stilbenoid derivatives, a sub-class of phenolic compounds which 
exhibit significant structural diversity and a wide range of biological activities [2, 3]. 
Over the past few years, our group has studied Carex species found in the northern 
regions of the United States, which have yielded several bioactive phenolic 
constituents, including resveratrol oligomers and other stilbenoids [4, 5].   
 
Hyperpigmentary disorders, such as melasma and freckles, are due to the abnormal 
accumulation of melanin.  The tyrosinase enzyme has been implicated as a key enzyme 
in melanogenesis, as it initiates an enzymatic cascade through the conversion of 
tyrosine and 3, 4-dihydroxyphenylalanine (DOPA) into DOPA-quinone [6, 7].  
Notably, plant natural products, in particular, phenolic compounds, have shown great 
promise as tyrosinase inhibitors, a primary example being the phenolic glycoside, 
arbutin, which is widely used for commercial cosmetic applications [8, 9]. Moreover, 
several phenolic sub-classes, including flavonoids, chalcones, and stilbenoids, are 
known to be tyrosinase inhibitors [10-12]. Therefore, in the current study, we sought 
to: 1) isolate and chemically characterize the constituents from the seeds of the 
previously uninvestigated Carex vulpinoidea and, 2) evaluate the isolates for their anti-
tyrosinase activities. 
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Herein we report the isolation and structure elucidation of two new phenolics, namely, 
vulpinoideols A (1) and B (2) (Figure 1), along with ten known compounds (3-12) 
(Figure 2) from C. vulpinoidea seeds. All of the isolates were evaluated for their 
tyrosinase inhibitory activity, along with the positive control, arbutin.   
 
Compound 1 had a molecular formula of C25H30O8 from the HRESIMS data 
corresponding to the quasimolecular ion at m/z 481.1835 [M + Na]+ (Figure 3). The 1H 
NMR spectrum (Figure 4) revealed a para- substituted aromatic ring system (ring A) 
with ortho-coupled- protons at δH 7.34 (2H, J = 8.5Hz) and δH 6.78 (2H, J = 8.5Hz); 
a second aromatic spin system (ring B) with meta-coupled protons at δH 6.74 (1H, J = 
2.1Hz) and δH 6.60 (1H, J = 2.1Hz); a trans-ethylene system with protons at δH 6.86 
(1H, J = 16.3Hz) and δH 7.14 (1H, J = 16.3Hz); an olefinic proton at δH 5.14 (1H, t J 
= 6.4Hz); one methylene, and two methyl groups and characteristic  signals of a β-
glucopyranose moiety, for which the resonance of the anomeric proton was at δH 4.86 
(J = 7.1Hz). 
 
The 13C NMR data (Figure 5) coupled with the HSQC spectra (Figure 6) revealed the 
presence of 25 carbons, and confirmed the presence of two aromatic rings, containing 
three oxygen-linked carbons, two alkene double bonds, and a sugar moiety. Detailed 
analysis of the 2D NMR data (including HSQC and HMBC) (Figures 6 and 7) allowed 
the structure elucidation of compound 1 (Figure 1).  The data revealed the presence of 
an isoprene group, which was confirmed through the following HMBC correlations, 
H-18/H-19 with C-16/C-17 and H-15 with C-16/C-17. 
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The placement of the isoprene group at position C-14 was based on HMBC correlations 
of H-15 with C-9/C-13/C-14 (Figure 1).  The β-glucopyranose moiety was placed at 
position C-13 based on the HMBC correlation of the anomeric proton H-1a to C-13.  
Further HMBC correlations, including H-12 with C-10/C-11, and H-10 with C-12/C-
13/C-14, allowed for the arrangement of substituents in ring B.  Additional key HMBC 
correlations, H-7 to C-1/C8 and H-8 to C/-7C-10/C-14 indicated the presence of a C6-
C2-C6, 1, 2-diphenylethylene moiety.  This backbone is characteristic of a monomeric 
stilbene derivative and, therefore, compound 1 was elucidated as depicted and assigned 
the common name of vulpinoideol A.  
 
Compound 2 (vulpinoideol B) was identified with a molecular formula of C26H32O9, 
corresponding to a quasimolecular ion peak at m/z 511.1937 [M + Na]+ (Figure 9). 
Compared with compound 1, vulpinoideol B (2) had the addition of a carbonyl carbon 
(C-8a, 206.2Hz), as well as the saturation of the alkene linkage between the aromatic 
spin systems, δH 2.90 (2H, t) and δH 3.16 (2H, t) (Figure 10).  These differences 
suggested the backbone of a saturated chalcone.  Similar to vulpinoideol A (1), 
vulpinoideol B (2) retained the ortho-coupled aromatic protons (δH 7.04, 2H, J = 8.2Hz 
and δH 6.69, 2H, J = 8.2Hz). However, its second aromatic system contained two 
isolated protons at δH 6.62 (1H, s) and δH 7.72 (1H, s) (Figure 11).  
 
The 13C NMR (Figure 12) and HMBC data (Figure 13) were again indicative of an 
isoprene substituent, as well as a β-glucopyranose moiety, which had its anomeric 
proton at δH 5.02 (J = 6.9 Hz).   The placement of the isoprene unit at C-13 was 
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confirmed using similar HMBC correlations as vulpinodeol A (1) i.e. H-15 with C-
14/C-13/C-12. Additionally, the HMBC correlation between the anomeric proton of 
the sugar, H-1a and C-12 allowed for the placement of the sugar moiety at C-12.  The 
HMBC correlations H-14 and H-8 with C-8a, and H-7 with C-8/C-5 confirmed the 
structure of the backbone (Figure 1).  
 
The inhibitory effects of all the isolates on mushroom tyrosinase enzyme were 
evaluated along with arbutin, the positive control.  Among the isolates, only the new 
compound, vulpinoideol B (2), as well as the known compounds, hopeaphenol (4) and 
the α-hydroxychalone (8) were more active than arbutin (IC50 values of 49.4, 6.1, 29.1 
vs 72.6µM, respectively).  The IC50 values of all the other isolates, including the new 
compound, vulpinoideol A (1) (IC50 = 151µM), exceeded 100µM.  
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2. Experimental 
General: Semi-preparative HPLC separations were performed on a Hitachi Elite 
LaChrom system consisting of an L2130 pump, an L-2200 autosampler, and an L-2455 
diode array detector, all operated by EZChrom Elite software, using a Phenomenex 
C18 column (250 × 10mm, 5μm), with a flow rate of 3mL/min. Medium pressure liquid 
chromatography (MPLC) separations were carried out on a prepacked C18 column (37 
× 5.5cm; ﬂow rate 3mL/min), and a liquid chromatography DLC-10/11 Isocratic pump 
(D-Star Instruments, Manassas, VA, USA). All solvents were either ACS or HPLC 
grade and were obtained from Wilkem Scientiﬁc (Pawcatuck, RI, USA). Sephadex 
LH20 resin (Amersham Biosciences) was packed in a glass column (3 × 70cm) and 
eluted with a 100% methanol mobile phase.  HRESIMS data was acquired using a 
Synapt G2-S QTOF mass spectrometer (Waters, Milford, MA). 
 
Plant material: The seeds of Carex vulpinoidea were collected on July 22, 2010 at the 
Susquehanna University CEER (Center for Environmental Education and Research) 
property in Pennsylvania, USA. A voucher sample (CM# 507015) is deposited at the 
Carnegie Museum Herbarium in Pittsburg (PA, USA).  
 
Extraction and separation: The seeds were ground (39.6g) and exhaustively extracted 
sequentially with hexanes, acetone, and methanol (each 3 times, 150mL per solvent for 
24h, each extraction).  The acetone extract (2.03g) was subjected to C18 reverse phase 
MPLC with a gradient solvent system of MeOH: H2O (40:60-100:0 v/v) to afford 
fractions 1-8. Fraction 1 (575.3mg) was eluted through the Sephadex LH20 column to 
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afford fractions 9-15.  Fraction 12 (426.6mg) was subjected to reverse phase C18 
MPLC (gradient, MeOH:H2O, 30:70-50:50, v/v) to yield hopeaphenol (4, 18.6mg) [13] 
and grandiphenol A (5, 24.1mg) [14]. 
 
Fraction 5 (19.9mg) was eluted through the Sephadex LH20 column to afford sub-
fractions 16-28.  Two compounds, 3,5,5′,7′-tetrahydroxyflavone (6, 3.4mg) [15] and a 
benzofuran (3, 2.1mg) [16], were isolated from fraction 22 (30.4mg) using semi-
preparative reverse phase C18 HPLC (isocratic, 55:45 MeOH:H2O, v/v).  Similarly, 
fraction 6 (384.7mg) was chromatographed on the Sephadex LH20 column to afford 
sub-fractions 29-35, and further separation of sub-fraction 30 (50.9mg) by C18 HPLC 
(gradient, MeOH:H2O, 50:50-100:0, v/v) yielded 3′,4′,7-trihydroxyflavone (7, 2.7mg) 
[17], vulpinoideol A (1, 3.4mg) and α-hydroxychalone (8, 4.4mg) [18].  Butein (9, 
15.1mg) [19] was isolated from sub-fraction 32 by C18 HPLC (isocratic, MeOH:H2O, 
77:23, v/v).  Methylated naringenin (10, 1.8mg) [20], vulpinoideol B (2, 2.2mg), and 
luteolin (11, 4.8mg) [5] were obtained from fraction 6 by C18 HPLC (gradient, 
MeOH:H2O, 60:40 – 70:30, v/v). Bavachalcone (12, 1.3mg) [21] was isolated from 
fraction 9 using Sephadex LH20, followed by C18 HPLC purification (isocratic, 
MeOH:H2O, 70:30, v/v).  
 
Vulpinoideol A (1) 
White amorphous solid. 
UV (MeOH) λmax: 305, 210 nm. 
1H NMR and 13C NMR: Table 1. 
HRESIMS: m/z [M + Na]+ calc. for C25H30O8: 458.5009; Found: 481.1835. 
 
Vulpinoideol B (2) 
Light yellow amorphous solid. 
UV (MeOH) λmax: 330, 275, 210 nm. 
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1H NMR and 13C NMR: Table 1. 
HRESIMS: m/z [M + Na]+calc. for  C26H32O9: 488.5269; Found: 511.1937. 
 
Tyrosinase inhibition assay: The tyrosinase assay was carried out similarly to Zhang 
and co-workers [22].  Briefly, mushroom tyrosinase, L-tyrosine and the positive 
control, 4-hydroxyphenyl β-D-glucopyranoside (arbutin) were purchased from Sigma-
Aldrich (St. Louis, MO). Tyrosinase inhibition assays were performed in 96-well 
microplate format using a SpectraMax M2 microplate reader (Molecular Devices, CA).  
Test samples were dissolved in DMSO at a concentration of 2.0mM and then diluted 
to different concentrations with phosphate buffer (0.1M, pH 6.8).  Each well contained 
40μL of sample with 80μL of phosphate buffer solution, 40μL of tyrosinase 
(100units/mL), and 40μL L-tyrosine (2.5mM). The mixture was incubated for 30min 
at 37°C and absorbance was measured at 490nm. Each sample was accompanied by a 
blank, containing all components except L-tyrosine. Arbutin was used as the positive 
control.  The results were compared with a negative control consisting of 10% DMSO 
in place of the sample. The percentage of tyrosinase inhibition was calculated as 
follows: 
[(ΔAcontrol − ΔAsample)/ ΔAcontrol] × 100  
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Table 1 1H NMR and 13C NMR data of Vulpinoideols A and B. 
 
Vulpinoideol A Vulpinoideol B 
No. δC δH (mult, J in Hz) δC δH (mult, J in Hz) 
1 127.3 7.34 (2H, d, 8.5) 130.3 7.04 (2H, d, 8.2) 
2 115.1 6.78 (2H, d, 8.5) 116.1 6.69 (2H, d, 8.2) 
3 157.0 -  156.8 - 
4 115.1 6.78 (2H, d, 8.5) 116.1 6.69 (2H, d, 8.6) 
5 127.3 7.34 (2H, d, 8.5) 130.3 7.04 (2H, d, 8.2) 
6 129.3 - 133.0 - 
7 129.6 6.86 (d, 16.3) 31.3 2.90 (2H, t) 
8 123.4 7.14 (d, 16.3) 41.5 3.16 (2H, t) 
8a  ** ** 206.2 - 
9 138.4 - 115.1 - 
10 105.5 6.74 (d, 2.1) 164.3 - 
11 155.7 - 103.3 6.62 (s) 
12 101.9 6.60 (d, 2.1) 162.9 - 
13 156.3 - 123.5 - 
14 120.0 - 131.8 7.72 (s) 
15 24.0 3.40/3.56 (m) 28.5 3.28 (m) 
16 124.4 5.14 (t, J=6.4) 123.4 5.31 (t) 
17 129.4 - 133.9 - 
18 16.8 1.83 (3H, s) 17.9 1.71 (3H, s) 
19 24.5 1.68 (3H, s) 25.9 1.75 (3H, s) 
1a 101.5 4.86 (7.1) 101.3 5.02 (6.9) 
2a 73.5 3.50 (m) 78.3 3.51 
3a 76.7 3.44 (m) 74.8 3.48 
4a 69.8 3.44 (m) 71.2 3.44 
5a 76.9 3.49 (m) 78.3 3.51 
6a 61.1 3.74/3.94 (dd) 62.3 3.71, 3.90 
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Table 2:  Tyrosinase Enzymatic Inhibition Activity of two new compounds, 
Vulpinoideols A and B, as well as other highlighted C. vulpinodea isolates. Arbutin 
(*) has been used a positive control.  
 
 
Compounds IC50 (µM) Std dev. 
Vulpinoideol A (1) 150 6.0 
Vulpinoideol B (2)  49.4 13 
Hopeaphenol (4) 6.10 1.2 
Grandiphenol A(5) 174 5.8 
α-hydroxychalcone (8) 29.1 0.3 
Bavachalcone (12) 122 7.9 
Arbutin* 72.6 7.9 
 
  
 52 
 
 
Figure 1: Selected HMBC correlations (HC) of vulpinoideol A (1) and 
vulpinoideol B (2) (top to bottom, respectively). 
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Figure 2: Known isolates from C. vulpinoidea 
  
3 
5 
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Figure 3. Vulpinoideol A. High Resolution Mass Spectrometry Data. 
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Figure 4. Vulpinoideol A -1H NMR spectrum. Data was measured in CH3OD at 500 
MHz (1H) and 125 MHz (13C). 
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Figure 5. Vulpinoideol A- 13C NMR spectrum. Data was measured in CH3OD at 500 
MHz (1H) and 125 MHz (13C). 
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 Figure 
6. Vulpinoideol A - NMR HSQC spectrum. Data was measured in CH3OD at 500 
MHz (1H) and 125 MHz (13C). 
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Figure 7. Vulpinoideol A - NMR HMBC spectrum. Data was measured in CH3OD at 
500 MHz (1H) and 125 MHz (13C). 
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Figure 8. Vulpinoideol A - NMR COSY spectrum. Data was measured in CH3OD at 
500 MHz (1H) and 125 MHz (13C). 
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Figure 9. Vulpinoideol B. High Resolution Mass Spectrometry Data. 
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Figure 10 Vulpinoideol B – 1H NMR spectrum. Data was measured in CH3OD at 500 
MHz (1H) and 125 MHz (13C). 
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Figure 11. Vulpinoideol B - NMR HSQC spectrum. Data was measured in CH3OD at 
500 MHz (1H) and 125 MHz (13C). 
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Figure 12 Vulpinoideol B - 13C NMR spectrum. Data was measured in CH3OD at 500 
MHz (1H) and 125 MHz (13C). 
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Figure 13. Vulpinoideol B - NMR HMBC spectrum. Data was measured in CH3OD at 
500 MHz (1H) and 125 MHz (13C). 
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Figure 14. Vulpinoideol B - NMR COSY spectrum. Data was measured in CH3OD at 
500 MHz (1H) and 125 MHz (13C). 
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CHAPTER 2 
GALLOTANNINS 
 
Manuscript 3 appears as published: 
Structure Activity Related, Mechanistic, and Modeling Studies of Gallotannins 
containing a Glucitol-Core and α–Glucosidase. Ma, Hang; Wang, Ling; Niesen,  Daniel 
B.; Cai, Ang; Cho, Bongsup P.; Tan, Wen; Gu, Qiong; Xu, Jun; and Seeram,  Navindra 
P. (2015). RSC Advances. 5, 107904-107915………………………………………...70 
Synthesis of tetragalloylglucitol (maplexin J)…………………………………...….108 
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ABSTRACT 
The incidence of type 2 diabetes mellitus is increasing rapidly worldwide and has 
become a significant public health burden [1]. Among various strategies used for type 
2 diabetes management, clinical α-glucosidase inhibitory drugs, such as acarbose, are 
utilized to inhibit the activity of carbohydrate hydrolyzing enzymes and thus decreasing 
postprandial hyperglycemia [2]. Over the past decade, there has been renewed scientific 
interest in identifying plant-based α-glucosidase inhibitors for the treatment and 
management of diabetes. Moreover, since these purified natural products could serve 
as important leads in the development of new classes of glucosidase inhibitors, the 
synthesis of analogs have also attracted a considerable amount of scientific interest [3].     
 
Our laboratory previously isolated a series of α-glucosidase inhibitory gallotannins, 
named maplexins A-I, from the red maple (Acer rubrum) species [4, 5]. These 
compounds contained mono-, di-, and tri-galloyl substituents located at different 
positions on a 1, 5-anhydro-D-glucitol moiety. Interestingly, the α-glucosidase 
inhibitory activities of these maplexins increased with the number of galloyl 
substituents, and a trigalloyl substituted maplexin was 20-fold more potent than the 
clinical drug, acarbose [5]. However, since a tetra-galloyl substituted maplexin was not 
obtained in our previous natural product isolation studies, a total synthesis is required 
to further evaluate the class of compounds and its α-glucosidase inhibitory activity. 
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To investigate the ligand-enzyme interaction, several biophysical methods including 
binding domains, modifications of hydrophobic surfaces, and secondary structural 
conformational changes were explored. Enzymatic kinetics and biophysical tools, 
including isothermal titration calorimetry (ITC), fluorescence, and circular dichroism 
(CD) spectroscopic methods, were used to elucidate the inhibitory mechanisms of the 
gallotannins against the α-glucosidase enzyme. Computational manipulation of 
homology modeling and molecular docking were also performed to support the 
prediction of binding interactions between the gallotannins and α-glucosidase. 
 
With a synthetic route established for maplexins E and J, through a collaborative 
publication with Dr. Hang Ma (Manuscript 3), we were able to continue the 
investigation of the ligand-enzyme interaction of the class of gallotannins and their 
target enzyme α-glucosidase. As a collaborative publication, Dr. Ma’s contribution 
specifically, sections: 2.2 measurements of α-glucosidase inhibitory assay, 2.3 
kinetics of α-glucosidase inhibition, 2.5 hydrophobic interactions of α-glucosidase 
using bis-ANS, 2.6 mircular dichroism (CD) spectroscopy, table 1, table 3, figure 2, 
figure 4, and the resultant analysis of that data found in sections: 2.2, 2.3, 2.5, 2.6, 
table 1, table 3, figure 2,, appear in Dr. Ma’s dissertation (Dr. Hang Ma Dissertation, 
Phytochemical and biological investigation of gallotannins from red maple (Acer 
rubrum) species, University of Rhode Island, 2014).   
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Abstract 
Gallotannins containing a glucitol core, which are only produced by members of the 
maple (Acer) genus, are more potent α-glucosidase inhibitors than the clinical drug, 
acarbose. While this activity is influenced by the number of substituents on the 
glucitol core (e.g. more galloyl groups leads to increased activity), the mechanisms 
of inhibitory action are not known.  Herein, we investigated ligand-enzyme 
interactions and binding mechanisms of a series of ‘glucitol-core containing 
gallotannins (GCGs)’ against the α-glucosidase enzyme. The GCGs included 
ginnalins A, B and C (containing two, one, and one galloyl/s, respectively), maplexin 
F (containing 3 galloyls) and maplexin J (containing 4 galloyls).  All of the GCGs 
were noncompetitive inhibitors of α-glucosidase and their interactions with the 
enzyme were further explored using biophysical and spectroscopic measurements. 
Thermodynamic parameters (by isothermal titration calorimetry) revealed a 1:1 
binding ratio between GCGs and α-glucosidase. The binding regions between the 
GCGs and α-glucosidase, probed by a fluorescent tag, 1,1′bis(4-anilino-5-
napththalenesulfonic acid, revealed that the GCGs decreased the hydrophobic 
surface of the enzyme.  In addition, circular dichroism analyses showed that the 
GCGs bind to α-glucosidase and lead to loss of the secondary α-helix structure of 
the protein.  Also, molecular modeling was used to predict the binding site between 
the GCGs and the α-glucosidase enzyme. This is the first study to evaluate the 
mechanisms of inhibitory activities of gallotannins containing a glucitol core on α-
glucosidase.  
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1. Introduction 
 
In mammals, enzymes involved in the carbohydrate metabolic pathways have been 
the therapeutic targets for various diseases, including diabetes, cancer, and viral 
infections [1-3]. Among these enzymes, the group of glucosidases (EC 3.2.1.20) 
plays a crucial role in carbohydrate metabolism by catalyzing the cleavage of 
glycosidic linkage of oligosaccharides or glycoconjugates to release mono-
saccharides [4].  Inhibition of glucosidase hinders glucose absorption and 
consequently decreases postprandial blood glucose levels. Development of 
αglucosidase inhibitors, as a class of antidiabetic medications for type II diabetes 
mellitus (T2DM), has attracted significant scientific attention [5]. In fact, several 
synthetic α-glucosidase inhibitors (AGIs), including acarbose, miglitol, and 
voglibose, are widely used as clinical treatment options for T2DM [6, 7]. However, 
adherence to synthetic AGI, as prescription medications, has suffered due to 
prominent undesirable side effects, including flatulence, diarrhea, and abdominal 
pain [8].  Conversely, naturally occurring AGIs, isolated from medicinal plants and 
medicinal foods, offer an attractive dietary strategy for T2DM management since 
they tend to be safe, and have fewer adverse effects than synthetic AGIs [9].   
 
The maple (Acer) genus is widely regarded for certain species including the sugar 
maple (Acer saccharum) and red maple (Acer rubrum) species, the sap of which are 
collected and concentrated to produce the natural sweetener, maple syrup [10]. 
Interestingly, in the plant kingdom, only members of the maple (Acer) genus are 
 73 
 
reported to produce gallotannins containing a glucitol instead of a glucose core 
which is most commonly found in gallotannins [11-16]. 
 
Our group and others have shown that these ‘glucitol-core containing gallotannins 
(GCGs)’ display potent α-glucosidase inhibitory properties which is influenced by 
the number, type, and location of substituents on their glucitol core [14-17].  In 
addition, our group showed that a red maple bark extract, enriched in GCGs, was 
similar in activity as acarbose, in lowering blood glucose in an animal model [18]. 
Therefore, GCGs represent an interesting polyphenol sub-class of plant natural 
products which show great promise as natural AGIs.   
 
In our group’s research efforts to identify natural AGIs, we reported on a series of 
new GCGs, named maplexins E-I, from the red maple (Acer rubrum) species [14-
16]. The GCGs feature different numbers and positions of galloyl groups attached 
to a 1,5-anhydro-D-glucitol core and exhibited 20-fold higher potency than acarbose 
which increased with the number of galloyl groups on the glucitol moiety. However, 
since these naturally occurring/isolated GCGs only contained three galloyl groups at 
the most, in an effort to broaden our test panel of GCGs, we synthesized a 
tetragalloylglucitol analog assigned the common name of maplexin J.  Indeed, 
maplexin J was found to be three times more potent than maplexins E and F (contain 
trigalloyls), and 70 times more potent than the competitive inhibitor acarbose (see 
Table 1), confirming our previous SAR observations.  In the current study, we have 
focused our attention on investigating the mechanisms of inhibitory actions of these 
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GCGs on the α-glucosidase enzyme. This research project was also prompted, in 
part, by the fact that other natural AGIs, such as 1-deoxynojirimycin, resveratrol, 
and oxyresveratrol, show different mechanisms of action against α-glucosidase [20-
21].    
 
The mechanisms of inhibition of compounds on the α-glucosidase enzyme can be 
investigated by several biophysical methods including binding domains, 
modifications of hydrophobic surfaces, and secondary structural conformational 
changes of enzymes induced by binding ligands [21]. In this study, enzymatic 
kinetics and biophysical tools, including isothermal titration calorimetry (ITC), 
fluorescence, and circular dichroism (CD) spectroscopic methods, were used to 
elucidate the inhibitory mechanisms of the GCGs against the α-glucosidase enzyme. 
Computational manipulation of homology modeling and molecular docking were 
performed to support the prediction of binding actions between the GCGs and the 
αglucosidase enzyme.  
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2. Experimental 
2.1 Chemicals.   
α-Glucosidase (EC 3.2.1.20) from Saccharomyces cerevisiae, p-nitrophenyl-α-D-
glucopyranoside (pNPG), and bis-8-anilinonaphthalene-1-sulfonate (bis-ANS) were 
purchased from Sigma Aldrich (St. Louis, MO).   All other chemicals were analytical 
reagent grade and were purchased from Sigma Aldrich, unless otherwise specified.  
The naturally occurring GCGs (Figure 1): ginnalin A (GA; contains two galloyls), 
ginnalin B (GB; contains one galloyl), ginnalin C (GC; contains one galloyl) and 
maplexin F (MF; contains three galloyls) were isolated from the red maple species 
as previously reported [14, 15].   
  
2.2 Measurements of α-glucosidase inhibitory assay.  
A mixture of 50μL test samples and 100μL 0.1M phosphate buffer (pH 6.9) 
containing yeast α-glucosidase solution (1.0 U/mL) were incubated in 96-well plates 
at 25°C for 10minutes. After pre-incubation, 50μL of 5mM pnitrophenyl-α-D-
glucopyranoside solution in 0.1M phosphate buffer (pH 6.9) were added to each well 
at timed intervals. The reaction mixtures were incubated at 25°C for 5 minutes. 
Before and after incubation, absorbance was recorded at 405nm by a micro-plate 
reader (SpectraMax M2, Molecular Devices Corp., operated by SoftmaxPro v.4.6 
software, Sunnyvale, CA) and compared to that of the control which had 50μL buffer 
solutions in place of the samples. The α-glucosidase inhibitory activity was 
expressed as inhibition % and was calculated as: Inhibition % = 100 × [(C5 – C0) – 
(S0 – S0)] / (C5 – C0), where C0 is the absorbance of the reagent blank in 0 minute, 
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S0 the absorbance of the samples in 0 minute, C5 the absorbance of the reagent blank 
in 5 minutes, and S5 the absorbance of the samples in 5 minutes [22].  
 
2.3 Kinetics of α-glucosidase inhibition.   
The inhibition types of ginnalin A (GA), maplexin F (MF), and maplexins J (MJ) 
were determined from Lineweaver–Burk plots, using previously reported methods 
with minor modifications [23]. Typically, two concentrations around the IC50 values 
of each sample were chosen (ranging from 2 – 250μM). For each concentration, α-
glucosidase activities were tested by using different concentrations of pPNP 
glycoside (1 to 1000μM). The mixtures of the enzyme and the inhibitor were 
dissolved in 50mM phosphate buffer (pH 6.8), and pre-incubated at room 
temperature for 30 minutes, and then the substrate was added. The enzymatic 
reaction was carried out at room temperature for 60 seconds, and monitored 
spectrophotometrically by measuring the absorbance at 405nm. Inhibition types of 
the inhibitors were determined by double-reciprocal plots.  
 
2.4 Titration microcalorimetry.  
Isothermal titration calorimetry (ITC), used to determine the thermodynamic 
properties between the GCGs and α-glucosidase, were measured with a VP-ITC 
Microcalorimeter (MicroCal, Northampton, MA, USA) according to previously 
reported methods with modifications [24]. A typical titration experiment consisted 
of 17 consecutive injections at 240s intervals consisting of 14μL injections of each 
GCGs into the titration cell at 25°C in phosphate buffer (pH 7.0, 100mM). The 
 77 
 
titration cell was stirred continuously at 310 rpm. The GCGs (1-4mM) and α-
glucosidase enzyme (0.026-0.031mM) were dissolved in the same phosphate buffer 
and degassed for 20 mins under vacuum using a ThermoVac (MicroCal, 
Northampton, MA, USA) prior to each experiment. Controls included buffer 
injected into buffer and GCGs injected into buffer solutions, respectively. Data was 
analyzed by using nonlinear regression with a single-site binding model in VP 
Viewer 2000, which uses the scientific plotting software, ORIGIN 7 (Origin Lab. 
Corp., Northampton, MA, USA).  
 
2.5 Hydrophobic interactions of α-glucosidase using bis-ANS.   
 α-glucosidase (2μM) was incubated in the presence of various concentrations of the 
GCGs (0-80μM) at 37°C for 5 minutes. Bis-ANS (5μM) was then added, and 
fluorescence was measured after incubation at 37°C for 15 minutes (λex = 400nm, 
λem = 440−600 nm) [25].  
 
2.6 Circular dichroism (CD) spectroscopy.  
 Far UV CD measurements (190-240nm) were conducted on a Jasco J-810 
spectropolarimeter equipped with a Peltier temperature controller at 25°C. Briefly, 
2μM of α-glucosidase was treated with various concentrations of the GCGs (0-
80μM). The samples were dissolved in 200µL of a sodium phosphate buffer (0.1M, 
pH 6.8) and placed in a 1.0mm path length cell.  The spectra was collected and 
corrected by subtraction of a blank 0.1M sodium phosphate buffer (pH 6.8), reducing 
noise and smoothing [26]. The changes of secondary structure of α-glucosidase were 
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estimated according to a method in the DichroWeb program, an online server for 
protein secondary structure analyses from the CD spectroscopic  
data [27, 28]. 
 
2.7 Homology modeling of α-glucosidase.   
The Saccharomyces cerevisiae α-glucosidase was downloaded from the UniProt 
protein knowledgebase (accession number P53341) [29]. The structure of isomaltase 
from Saccharomyces cerevisiae (PDB entry 3A4A) that shared a 71.8% sequence 
identity and 87.1% sequence similarity with Saccharomyces cerevisiae α-
glucosidase based on National Center for Biotechnology Information Basic Local 
Alignment Search Tool (NCBI BLAST) search results was selected as the template 
for homology modeling. Sequence alignment and structural model building were 
performed using DS 3.5 (Discovery Studio, version 3.5, Accelrys, Inc., San Diego, 
CA, USA). Ten initial 3D α-glucosidase structures were constructed and sorted in 
ascending order of PDF total energy score. The best structure with the most negative 
score was selected for further refinements.  
 
2.8 Refinement of 3D α-glucosidase structure.  
Molecular dynamics (MD) simulation is widely used for both homology and X-ray 
structural refinement [30, 31].  The initial best 3D α-glucosidase structure from 
homology modeling was refined through MD simulations using Amber12 [32]. The 
initial structure was solvated in an octahedron periodic box (based on the TIP3P 
model) with 12Å of water along each dimension. The protein was applied with the 
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Amber ff99SB force field and counter-ions were added to the system to neutralize 
charges [33]. 
 
MD simulations consisted of energy minimization, heat phase, equilibration, and 
production. The solvated system was minimized by three steps. First, a harmonic 
constraint potential of 10kcal/mol/Å2 was applied to all atoms except water 
molecules. Second, the protein backbone atoms were restrained with a force of 
5.0kcal/mol/Å2. Finally, all atoms were allowed to move freely. In each step, energy 
minimization was executed by the steepest descent method for the first 2000 steps 
and the conjugated gradient method for the subsequent 2000 steps. After 
minimization, the system was gradually heated in the canonical “NVT ensemble” 
from 0 to 300 Kelvin (K) in 100 picoseconds (ps) using a Langevin thermostat with 
a coupling coefficient of 1.0ps with a force constant 10kcal/mol/Å2 on the protein. 
The system was then equilibrated for the first two 500ps and subsequent three 200ps 
at 300K with decreasing restraint weights reduced from 10 to 0.2kcal/mol/Å2.  A 
production simulation run for 10ns was lastly performed at 300K. During the MD 
simulations, the long-range Coulombic interactions were handled using the particle 
mesh Ewald (PME) method and the cutoff distance for the long-range van der Waals 
(vdW) energy term was set at 10.0Å [34]. All hydrogen atoms were constrained 
using the “SHAKE” algorithm and the time step was set at 2 femtosecond. 
Coordinate trajectories were recorded every 2ps. The refined 3D α-glucosidase 
structure was obtained from last snapshot of MD simulations and validated by 
Profiles-3D Verify module in DS 3.5.  
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2.9 Molecular docking.  
GA, MF, and MJ were optimized using MMFF94s force field. The refined 
αglucosidase structure from MD simulations was protonated based on amber99 force 
field after removing water molecules. To obtain the most plausible binding sites, we 
searched the whole 3-D space of the receptors, including both the active-site 
(Asp214, Glu276 and Asp349) and non-active-site regions. Site Finder module 
encoded in MOE (MOE 2010.10. Chemical Computing Group, Inc. Montreal, 
Canada) was employed for detecting potential ligand binding sites of α-glucosidase. 
MOE-docking was employed to identify the binding poses of GA, MF, MJ and α-
glucosidase. During docking study, 30 poses per compound were retained. All 
docked poses of GA, MF, and MJ were ranked on the basis of the binding docking 
energies according to London G score [35, 36]. The best conformation for each 
compound from clustering results was chosen for binding mode analyses.   
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3. Results 
3.1 Comparison of α-glucosidase inhibitory effects of GCGs   
As shown in Table 1, the inhibitory activities of the GCGs against the α-glucosidase 
enzyme increased with increasing number of galloyl groups attached to the 1,5-
anhydro-D-glucitol moiety.  The mono-galloyl substituted gallotannins (GB and 
GC) did not demonstrate any inhibitory activities on α-glucosidase (IC50 > 1000μM), 
and the di-galloyl gallotannin (GA) only showed a moderate inhibitory activity with 
an IC50 value of 216.43μM.  However, the activities of MF and MJ, which contain 
three and four galloyl groups, respectively, were significantly enhanced (IC50 = 
13.70 and 4.27μM, respectively).  The results indicated that MF and MJ were potent 
α-glucosidase inhibitors.  
 
To further evaluate the inhibitory characteristics of GA, MF and MJ, enzyme kinetic 
assays were performed and their inhibition types were determined by the 
Lineweaver-Burk plots (Figure 3).  The Lineweaver-Burk plot of each GCG (at 
different concentrations ranging from 2 – 250μM) generated straight lines that all 
intersected the X-axis at the same point, suggesting that the GCGs were typical 
noncompetitive inhibitors of α-glucosidase. Therefore, this implied that GA, MF, 
and MJ bind to the noncompetitive site of the yeast’s α-glucosidase enzyme rather 
than to the catalytic domain of the enzyme.  
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3.2 ITC measurement  
The thermodynamic properties of the binding interaction between the GCGs and α-
glucosidase complex were determined by using ITC.  The titration peaks of GA, GB, 
and GC (at concentrations ranging from 1-4mM) were too weak to yield 
thermodynamic parameters. However, the titration peaks for MF or MJ 
(concentrations ranging from 1-2mM) showed binding interactions that were 
typically exothermic (see Figure 3). The thermodynamic parameters for GA, MF, 
and MJ, obtained from the ITC analyses, are summarized in Table 2.  Both MF and 
MJ had a ligand:enzyme ratio (N value) of 1:1 indicating that one molecule of each 
of these GCGs binds to one molecule of the enzyme [37].  In addition, the binding 
constants (Ka) of MF or MJ with α-glucosidase were 2.85 x 104 and 4.22 x 104 mol-
1, respectively. The stronger binding affinity of MJ with α-glucosidase, compared to 
that of MF and the enzyme, was in agreement with the results obtained from the α-
glucosidase inhibitory assay with these GCGs (Table 1) [38]. The negative ΔG 
values for both MF and MJ (-6.09 and -6.31kcal/mol, respectively) suggested that 
their binding interactions were spontaneous [38, 39]. Furthermore, a positive ΔS 
value and a negative ΔH value for both MF and MJ indicated that their binding 
interactions with the α-glucosidase enzyme were enthalpy-driven [39, 40]. Notably, 
the thermodynamic parameters observed for MF and MJ are similar to those reported 
for the major gallotannin present in tea, namely, epigallocatechin gallate (EGCG), 
with lipase [38].  
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Given that a positive ΔS value may be associated with the first stage of binding 
interaction, [41, 42] where the ligand and enzyme are immobilized in a hydrophobic 
environment, we further examined the hydrophobic alteration of the α-glucosidase 
enzyme.  
 
3.3 GCGs reduced the hydrophobicity of α-glucosidase.    
Noncovalent fluorescent probes have been extensively used for the study of protein 
conformation [43, 44]. An external fluorescent probe such as bis-8-
anilinonaphthalene-1-sulfonate (bis-ANS) is sensitive to the protein 
microenvironment and selectively binds to the hydrophobic surface of protein [45].  
Therefore, a bis-ANS probe was utilized to assess the exposure of α-glucosidase 
hydrophobic surface induced by the ligands.  As shown in Figure 4, after being co-
incubated with α-glucosidase for 20min at 37°C, GA, MF, and MJ were able to 
decrease the fluorescence of the bis-ANS-enzyme complex in a concentration-
dependent manner. Although GA slightly decreased the fluorescent intensity of the 
bis-ANS-enzyme complex at the low concentration (20μM), compared to the non-
treatment group, the fluorescence of the MF and MJ treatment groups were 
significantly reduced. Moreover, all three ligands greatly decreased the fluorescence 
at concentration of 80μM, suggesting that GA, MF, and MJ could decrease the 
hydrophobic surfaces of α-glucosidase.   
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Since hydrophobic surface is crucial to facilitate the formation of the enzyme active 
site, GA, MF, and MJ could have possibly inhibited the α-glucosidase enzyme 
activity by inducing poor hydrophobic surfaces on the enzyme structure [46]. 
 
3.4 Change in conformation of α-glucosidase induced by GCGs. 
To further examine the effects of the GCGs on the secondary structure of α-
glucosidase, circular dichroism (CD) spectra of free αglucosidase and ligand-α-
glucosidase complex were acquired.  In Figure 5, the CD spectra of the free α-
glucosidase enzyme exhibited two characteristic negative bands at 208 and 222nm, 
indicating that the major secondary protein structure presented in the α-glucosidase 
was αhelix [47, 48]. When various concentrations (20-80μM) of the GCGs were co-
incubated with αglucosidase, the CD spectra of the ligand-enzyme complex was 
significantly altered indicating that the conformation of the enzyme protein was 
affected by the ligands in a concentration dependent manner.  As summarized in 
Table 3, the GCGs bind to the enzyme protein that mainly resulted in the loss of α-
helix conformation.  When 40μM of MF and MJ were delivered to α-glucosidase, 
the enzyme lost 4.9 and 5.6% of its α-helix conformation, respectively, which could 
potentially cause the loss of biological functions of the α-glucosidase enzyme.  
 
3.5 Homology modeling. 
Lacking the 3D structure of Saccharomyces cerevisiae α-glucosidase used in 
biological assays, we constructed a 3D homology structure of α-glucosidase by 
computational approach. The 3D homology models of α-glucosidase were generated 
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with the MODELER module in DS 3.5, and the best model with lowest PDF total 
energy score was refined by 10ns MD simulations (Figure 6B). Trajectory-based 
analysis showed that the root-mean-square deviation (RMSD) of the protein 
backbone atoms with reference to the initial structural coordinates increased slowly 
in the first 4 nanoseconds (ns) and then subsequently stabilized after 4 ns, suggesting 
that the α-glucosidase structure was stable.   
 
The refined structure from the last snapshot of MD simulations was validated via  
Profile-3D, Procheck, and Prostat analysis. The overall self-compatibility score 
generated by Profile-3D module in DS 3.5 for this refined model was 252.5 (the 
verified expected high score was 263.47, and the verified expected low score was 
118.56). Procheck was used to calculate the φ and ψ angles (Figure 6A) and four 
residues (Ser331, Glu522, Arg543, and Tyr372) were located in un-allowed regions, 
and the percentage of residues within the Ramachandran plot’s allowed regions was 
99.32%. Prostat analysis showed that almost all bond lengths, angles, and torsions 
stayed within a rational range. All of these validation results proved that the refined 
model is reliable.  
 
3.6 Binding modes analyses.  
A total of 35 potential ligand binding sites of the refined model were obtained from 
Site Finder module in MOE. The largest five binding sites (size>100) were selected 
for the docking study (Figure 6). As shown in Table 4, the three GCGs, namely, GA, 
MF, and MJ, shared the same scaffold, suggesting that they bind at the same site for 
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a given target.  Sites 2, 4, and 5 were not suitable for these compounds because the 
trends of the docking scores for GA, MF, and MJ were inconsistent with the 
corresponding enzyme assay results. For example, compound MF in binding site 4 
with a docking score of -17.37Kcal/mol is lower than that of compound MJ (-
15.03Kcal/mol) which is inconsistent with their enzyme inhibition values (13.70μM 
for MF and 4.27tμM for MJ). Similar trends were observed in the docking results of 
binding sites 2 and 5.   
 
As shown in Figure 7C, binding site 3 was located at two helix structures and the 
three GCGs showed considerable binding modes based on the docking score and the 
enzyme inhibition assay. As previous studies have suggested that the helix structure 
could be stabilized by targeting compounds with polyhydroxyl groups, [21, 23, 49] 
our CD results suggest that the helix structures were reduced with increasing 
concentrations of GA, MF, and MJ. Therefore, this implied that binding site 3 is not 
targeted by these GCGs.   
 
Binding site 1 is surrounded by coil, bend, and sheet structures, with little helix 
structures, which contain both active and inactive sites (Figure 7A). The trends of 
docking score of GA, MF, MJ, and the enzyme assay results are consistent. Based 
on all of the above analyses, the GCGs, GA, MF, and MJ target the binding site 1 of 
Saccharomyces cerevisiae α-glucosidase. The active site of α-glucosidase is 
comprised of Asp214, Glu276 and Asp349 and is represented by the red oval in 
Figure 8D. Superimposition of the binding modes of GA, MF, and MJ suggested 
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that all of the binding sites are located at the noncompetitive domain of α-
glucosidase (Figure 8A, B, and C), which are relatively close to the active site 
(Figure 8D). All of the docking results demonstrate that GA, MF, and MJ are 
noncompetitive inhibitors, in accordance with the aforementioned kinetic results 
(Figure 2).   
 
As shown in figure 8A, the hydroxyl group of GA can form two hydrogen bonds 
with the side chain of Ser244 and Phe157. One galloyl group of GA is inserted in 
the polar area comprised of Arg312, Glu304, Arg439, and Gln350, suggesting that 
a polar interaction can be formed. Moreover, the phenyl group can form favorable 
hydrophobic interactions with the side chains of Phe158, Phe157, His239, and 
His279. Compounds MF and MJ contain more galloyl groups than GA, suggesting 
that more favorable binding interactions will be formed against a given target 
according to Ge and coworkers’ results [50].  As shown in figures 8B and 8C, MF 
can form four hydrogen bonds with Asp408, Glu304, Ser244, and Phe157, whereas 
MJ can form eight hydrogen bonds with Glu304, Ser244, Ser299, Glu276, Arg212, 
Thr215, and Ala216. Thus, hydrogen bonds are formed via the hydroxyl groups of 
these GCGs. Notably, a similar phenomenon has been observed in other phenolic 
compounds such as xanthone derivatives [23], resveratrol, and oxyresveratrol [21]. 
Moreover, more favorable hydrophobic interactions are formed between MF and MJ 
and α-glucosidase residues (Phe157, Phe158, Leu237, His239, His279, Phe300, and 
Ala278 for MF, and Phe157, Pro309, Leu237, His239, Leu218, His279, and Arg312 
for MJ). These hydrophobic sites were occupied by GCGs, suggesting that the GCGs 
 88 
 
decreased the hydrophobic surface of the enzyme which was consistent with the data 
obtained from the bis-ANS assay. Also, the binding energy of GA, MF, and MJ is -
10.45, -13.02, and -16.35kcal/mol, respectively, which was in full accordance with 
results from the enzyme inhibition assay and binding model analyses.   
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4. Discussion 
The red maple (Acer rubrum) species is endemic to eastern North America and 
widely known for its tree sap which is used to produce the natural sweetener, maple 
syrup.  This plant has also been used by the Native Americans as an herbal medicine, 
and recent phytochemical and biological studies from our group on this species led 
to the discovery of several GCGs [14-16]. More importantly, these GCGs show 
potential as natural AGIs based on in vitro and animal studies [14-16, 18].  While 
several of these GCGs showed far more potent α-glucosidase inhibitory activities 
than the clinical drug, acarbose, their mechanisms of action remained unknown.  
Herein, we reveal several key mechanisms by which these GCGs interact with α-
glucosidase.   
 
First, the inhibition type of the GCGs against the α-glucosidase enzyme was found 
to be noncompetitive, suggesting that these gallotannins bind to the specific site of 
enzyme-substrate complex rather than the enzyme catalytic domain.  This binding 
pattern is in agreement with previous studies of a ‘glucose-core containing 
gallotannin’, namely, pentagalloyl glucose (PGG), which is also a noncompetitive 
α-glucosidase inhibitor [51]. It is noteworthy that this distinguishes the GCGs from 
acarbose, a synthetic AGI, which is known to be a competitive inhibitor that directly 
binds to the active site of α-glucosidase [52].  In addition, increasing the number of 
galloyl groups on the glucitol core enhanced the α-glucosidase inhibitory activities 
of these GCGs, an SAR effect that has also been observed in glucose-core containing 
gallotannin α-glucosidase inhibitors, namely, PGG and its analogs [51]. 
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Second, ITC analyses revealed that the binding stoichiometry between the GCGs 
(MF and MJ) and α-glucosidase was in a 1:1 ratio suggesting a single binding site 
for these compounds. This data is similar to that reported for the tea gallotannin, 
epigallocatechin gallate (EGCG) and lipase [38]. Additionally, the thermodynamic 
parameters (Table 2) revealed that the formation of the ligand-enzyme complex was 
spontaneous and enthalpy-driven suggesting that the binding interaction was largely 
attributed to the hydrogen bonding.  This is not surprising since it has been well 
established that gallotannins form hydrogen bonds with the polar residues of proteins 
through their galloyl and/or hydroxyl groups [53, 54]. This observation was further 
supported by our computational models.  Given that gallotannins-protein binding 
can be enthalpy-driven (by hydrogen bonding and protonation) [55-57], entropic 
factors (such as hydrophobic interactions) [41], are also often involved in the 
formation of ligand-protein complexes.  Therefore, we examined the hydrophobicity 
of the GCGs and α-glucosidase complex.   
 
The GCGs reduced the hydrophobic surface of the enzyme and impeded the 
formation of the active center of the α-glucosidase enzyme.  GA, MF, and MJ 
significantly decreased the α-helix conformation of the enzyme protein.  Since α-
helix is a rigid secondary structure that maintains many enzymatic protein functions, 
loss of this structure may result in enzyme destabilization.  Therefore, the major 
inhibitory mechanism of the GCGs against α-glucosidase mainly consists of binding 
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to the enzyme-substrate complex, reducing the hydrophobic surface, and changing 
the α-helix conformation of the enzyme protein.  
 
Lastly, the GCGs act as noncompetitive inhibitors that bind to a noncompetitive 
domain of α-glucosidase located at relatively close to the active site (Figure 7D). 
This noncompetitive domain is different from the binding pocket of acarbose 
(competitive inhibitor) [52]. The predicted noncompetitive binding site may provide 
a novel site for structure-based discovering and designing novel α-glucosidase 
inhibitors. The molecular docking results demonstrate that more galloyl groups in 
the GCGs leads to enhanced binding affinity against α-glucosidase. However, 
further in silico studies to investigate the dynamic mechanisms of whether GCGs 
could trigger the loss of the secondary α-helix of the flexible structures (binding sites 
of GCGs) is warranted and included in our group’s future studies.  
 
Therefore, overall, this study provides useful information on these GCGs which can 
be used to guide the design of new GCG analogs with superior activities against α-
glucosidase.  
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5. Conclusion  
In summary, we have determined the inhibition type of ‘glucitol-core containing 
gallotannins (GCGs)’.  The ligand-enzyme interaction was studied using several 
biophysical and spectroscopic tools including ITC, fluorescent probe and CD 
spectra. Our results showed that these GCGs had a single binding site, they could 
decrease the hydrophobic surfaces of the enzyme protein, and also reduce the α-helix 
conformation content of the protein’s secondary structure. Our study provides 
valuable information underlying the interactions between these GCGs and α-
glucosidase, a crucial step towards further investigating their potential as natural 
AGIs.  Further investigation of these GCGs will focus on in vivo studies to evaluate 
their safety and efficacy as potential dietary agents for T2DM management which is 
included in our group’s future planned studies. 
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Table 1: α-Glucosidase inhibitory activities of GCGs  
Compound   # of galloyl group  IC50 (μM) a  Type of inhibition  
ginnalin B (GB)  1  > 1000  n.d.  
ginnalin C (GC)  1  > 1000  n.d.  
ginnalin A (GA)  2  216.4 ± 3.19  noncompetitive  
maplexin F (MF)  3  13.70 ± 0.87  noncompetitive  
maplexin J (MJ)  4  4.270 ± 0.13  noncompetitive  
acarbose b  ─  142.4 ± 1.68  competitive  
a  
IC50 values are shown as mean ± S.D. from three independent experiments;  
b  
Positive control; n.d. = not determined.  
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Table 2: Thermodynamic parameters for GCGs [ginnalin A (GA); maplexin F 
(MF) and maplexin J (MJ)] binding to α-glucosidase enzyme  
  
Ligand  N [GCGs/α-
glucosidase]  
Ka[104  mol-1]  ΔG [kJ mol-1]  ΔH [kJ mol-1]  ΔS [J mol-1 K-1]  
GA  n.d.  n.d.  n.d.  n.d.  n.d.  
MF  1.01  2.85  -6.09  -10.26  14.06  
MJ  1.01  4.22   -6.31  -25.17  63.31  
n.d.: not detected  
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Table 3: The effect of GCGs (GA, MF, and MJ) on the secondary structure of α-
glucosidase enzyme  
 Ligands (Conc.)   α-Helix %  β-Fold %  β-Turns %  Unordered  
Control  36.3  21.9  14.3  26.9  
GA 40μM  37.8  22.7  11.5  27.8  
GA 80μM  33.5  22.5  15.8  27.7  
MF 20μM  30.7  24.7  15.6  28.4  
MF 40μM  31.2  22.7  16.6  28.9  
MJ 20μM  31.8  21.1  20.4  26.4  
MJ 40μM  30.7  24.4  19.1  25.3  
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Table 4: Detailed docking results for GA, MF, and MJ. Cluster represents the 
docking score of the lowest binding energy conformation of the more populated 
cluster.  
compound  GA  MF  MJ  
Site 1  Range  (-17.59, -8.53)  (-19.87, -11.98)  (-21.70, -9.40)  
 cluster  -10.54  -12.02  -16.53  
Site 2  Range  (-12.57, -5.78)  (-12.56, -6.80)  (-13.77, -6.39)  
 cluster  -8.44  -8.15  -9.14  
Site 3  Range  (-16.11, -6.47)  (-18.20, -8.70)  (-19.47, -7.70)  
 cluster  -11.27  -12.25  -13.04  
Site 4  Range  (-14.41, -5.28)  (-17.37, -6.43)  (-15.03, -5.90)  
 cluster  -10.26  -10.37  -9.86  
Site 5  Range  (-15.24, -7.46)  (-17.78, -6.23)  (-16.00, -7.53)  
 cluster  -11.32  -11.72  -11.06  
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Figure 1: Chemical structures of five ‘glucitol core containing gallotannins 
(GCGs)’: ginnalin A, ginnalin B, ginnalin C, maplexin F and maplexin J.  
  
 101 
 
 
Figure 2: Lineweaver-Burk plots of the kinetics of inhibition of GA (A), MF (B) 
and MJ (C) on α-glucosidase enzyme.  Two concentrations (ranging from 2 - 
250μM of ligands; close to their IC50 values) were co-incubated with α-glucosidase 
at 37°C for 30min, then pNPG was added at varying concentrations (from 1-
1000μM).  
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Figure 3: Results of isothermal titration calorimetry (ITC) for GCGs binding to α-
glucosidase: (Top) Raw data plot of heat flow against time for the titration of MF (A) 
or MJ (B) into 0.031mM α-glucosidase enzyme protein. (Bottom) Plot of molar 
enthalpy change against GCGs/αglucosidase enzyme molar ratio.   
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Figure 4: Fluorescence intensity of bis-ANS-α-glucosidase complex.  The changes 
of fluorescence intensity were induced by GA (A), MF (B) and MJ (C) at different 
concentrations ranging from 20 – 80μM.  
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Figure 5: Circular dichroism (CD) spectra of the α-glucosidase-GCG complex.  α-
glucosidase (2μM ) were  co-incubated with GA, MF, or MJ at 20-80μM at 37°C 
for 20 min.  
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Figure 6: The properties of the refined α-glucosidase structure. (A) Ramachandran 
plot for a 3D model of α-glucosidase (residues denoted with a + are outliers); (B) 
Time dependences of the root mean square deviations (RMSD) of the backbone 
atoms (Cα, N, O-atoms) with respect to initial structure.  
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Figure 7: Top five potential ligand binding site generated via Site Finder module in 
MOE2010.10. The binding site is represented by alpha sphere centers and red oval. 
The active site is comprised of catalytic residues (Asp 214, Glu276, and Asp349).  
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Figure 8: Binding modes for GA (A), MF (B), MJ (C), and superimposition of the 
binding modes of GA (red), MF (aquamarine blue), and MJ (blue). Hydrogen 
bonds are depicted by red dotted lines. Red oval represents the active binding site. 
 
 
 
  
 108 
 
Synthesis of tetragalloylglucitol (maplexin J)  
The tetragalloylglucitol gallotannin (assigned the common name of maplexin J (MJ)) 
was synthesized by modification of the previously published method as shown in 
Scheme 1 [19]. Briefly, gallic acid (i, 101mg, 0.6mmol) was dissolved in dry N,N-
dimethylformamide (DMF, 2mL). Imidazole (513mg, 7.5mmol) and tert-
butyldimethylsilyl chloride (TBDMS, 521mg, 3.5mmol) were added to the solution 
and stirred at room temperature under nitrogen atmosphere for 24 hours. A white 
crystalline product precipitated out of the reaction solution. Trisilyl-protected gallic 
acid (ii) was isolated (244mg, 82%) from the precipitant using silica gel column 
chromatography.  
Compound ii (187mg, 0.4mmol) and glucitol (iii, 10.4mg, 0.06mmol) were 
dissolved in dry dichloromethane (DCM, 2mL). N, N'-diisopropylcarbodiimide 
(DIC, 61.4mg, 0.5mmol) was added followed by 4-dimethylaminopyridine (DMAP, 
74.4mg, 0.06mmol). The mixture was stirred at room temperature under nitrogen 
atmosphere for 96 hours. The crude product was purified using silica gel column 
chromatography to yield compound iv.  
Compound iv (843mg, 64.6%) was isolated and its structure was confirmed by 2D 
NMR heteronuclear multiple bond correlations (HMBC) from the three sugar 
methines and the sugar methylene to the respective carbonyl carbons of the gallic 
acids. Deprotection of compound iv was accomplished in the presence of tetra-n-
butylammonium fluoride (TBAF). Compound iv (50mg, 0.023mmol) was dissolved 
in dry tetrahydrofuran (THF, 2mL). TBAF (61.1mg, 0.23mmol) was added, and the 
mixture was stirred at room temperature under a nitrogen atmosphere for 10 minutes. 
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The crude product was purified using reverse-phase high-pressure liquid 
chromatography (HPLC) to yield the final product (10mg, 52.3%), which was 
characterized as tetragalloylglucitol and assigned the common name of maplexin J 
(MJ) based on its nuclear magnetic resonance (NMR) spectroscopic data (Table 1; 
key HMBC correlations shown in Figure 1).  This scheme was carried out several 
times to synthesize enough maplexin J for further biological assays, fortunately 
maplexin E, a tri-galloylglucitol, was isolated and elucidated as an additional side 
product. 
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Scheme 1: Synthetic scheme of maplexin J.  
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Table 1. The 1H and 13C NMR data of maplexin J. Data was measured in CH3OD 
at 500 MHz (1H) and 125 MHz (13C).  
         
No.  
δC  δH (mult, J in Hz)  
Glucitol Sugar Core  
1  
  
  
66.6  
  
  
4.20 (m)  
3.54 (t, 11.1, 12.2)  
2  69.6 5.19 (ddd)  
3  73.8 5.65 (t, 9.9, 11.1)  
4   68.9  5.39 (t, 9.9, 10.7)  
5  76.7 3.94 (m)  
6  
  
62.3 
  
4.36 (d, 12.1)  
4.19 (m)  
Galloyl A 
1a  
  
118.9 
  
  
2a, 6a  108.9 6.88 (2H, s)   
3a, 5a  145.1   
4a  138.8   
7a  165.8   
Galloyl B 1b    
119.2 
  
  
2b, 6b  108.9 6.82 (2H, s)  
3b, 5b  144.8   
4b  138.6   
7b  166.2   
Galloyl C 
1c  
  
118.9 
  
  
2c. 6c  109.0  6.87 (2H, s)  
3c, 5c  145.0   
4c  138.8   
7c  165.6   
Galloyl D 
1d  
  
119.7 
  
  
2d, 6d  108.8 7.00 (2H, s)  
3d, 5d  145.0   
4d  138.5   
7d  166.6    
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Figure 1. Key HMBC correlations of maplexin J.  
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ABSTRACT 
Previous reports have demonstrated the ability of pomegranate extract (PE) and 
pomegranate juice (PJ) to attenuate Alzheimer’s disease (AD) pathogenesis in several 
transgenic animal models, as well as aiding in memory related tasks in humans [1-4]. 
Collectively, these findings suggest a role for pomegranate to augment memory 
function through task-related activities. The pomegranate fruit is a rich source of 
ellagitannins, most notably punicalagin. However, upon ingestion, ellagintannins are 
poorly absorbed in the gut and are quickly hydrolyzed releasing their hallmark 
‘hexahydroxydiphenyl’ substituent, which quickly undergoes an internal lactonization 
to generate ellagic acid.   Unfortunately, much like its parent compound, ellagic acid is 
not readily absorbed and does not reach physiologically relevant plasma 
concentrations. Ellagic acid is metabolized by the gut microflora into dibenzopyranone 
derivatives, known as urolithins. The urolithins, most notably urolithin A (UA; 3,8-
dihydroxy-6H-dibenzo(b,d)pyran-6-one) achieves biologically significant 
concentrations (20-100µM) in plasma and select tissues [5-7]. As ellagitannins are the 
major class of compounds found in pomegranate, we therefore hypothesize that the 
urolithins could be the neurologically active compounds responsible for the link 
between pomegranate and AD. 
 
Our first priority was to synthesize several of the most physiologically relevant 
urolithin derivatives including urolithin A (3,8-dihydroxybenzo[b,d]pyran-6-one), 
methyl-urolithin A (3-methoxy-8-hydroxybenzo[b,d]pyran-6-one), urolithin B (3-
hydroxy-6H-dibenzo[b,d]pyran-6-one) and methyl-urolithin B (3-methoxy-6H-
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dibenzo[b,d]pyran-6-one). Using these synthetic standards, LC-MS/MS methods have 
been developed in conjunction with cellular, tissue, and Caenorhabditis elegans, 
uptake studies.  
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Abstract 
Pomegranate shows neuroprotective effects against Alzheimer’s disease (AD) in 
several reported animal studies. However, whether its constituent ellagitannins and/or 
their physiologically relevant gut microbiota-derived metabolites, namely, urolithins 
(6Hdibenzo[b,d]pyran-6-one derivatives), are the responsible bioactive constituents is 
unknown. Therefore, from a pomegranate extract (PE), previously reported by our 
group to have anti-AD effects in vivo, 21 constituents, which were primarily 
ellagitannins, were isolated and identified (by HPLC, NMR, and HRESIMS). In silico 
computational studies, used to predict blood-brain barrier permeability, revealed that 
none of the PE constituents, but the urolithins, fulfilled criteria required for penetration. 
Urolithins prevented β-amyloid fibrillation in vitro and methyl-urolithin B (8-methoxy-
6H-dibenzo[b,d]pyran-6-one), but not PE or its predominant ellagitannins, had a 
protective effect in Caenorhabditis elegans post induction of amyloid β1−42 induced 
neurotoxicity and paralysis. Therefore, urolithins are the possible brain absorbable 
compounds which contribute to pomegranate’s anti-AD effects warranting further in 
vivo studies 
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1. Introduction 
 
 
Alzheimer’s disease (AD) is a degenerative brain disease that is projected to affect over 
115 million people worldwide by 2050. AD is a leading cause of disability and 
morbidity among patients and is among the most costly chronic diseases known to 
society. Apart from its public health burden, the economic cost of AD exceeded 200 
billion dollars for 2014 alone which is estimated to increase 5-fold by 2050 [1]. If the 
incidence of AD continues on its current trajectory, it will cripple the health care 
systems of several countries including the United States where it is the sixth leading 
cause of death [2]. Unfortunately, despite several decades of research, many approved 
drugs for AD have little effect on slowing disease progression. In fact, it is estimated 
that the brain changes for AD may begin more than 20 years before symptoms of the 
disease appear and it is often too late to reverse AD pathology by the time of diagnosis. 
Therefore, it is imperative that other approaches, such as the utilization of natural 
products as dietary intervention strategies, be explored as preventive and/or disease-
modifying measures to slow or stop AD progression. 
 
Among natural compounds, plant polyphenols have emerged as an important 
nonpharmacologic approach for AD prevention and treatment [3,4]. However, the 
majority of polyphenols, including the subclass known as ellagitannins, are poorly 
absorbed in the small intestine and do not achieve physiologically relevant 
concentrations in circulation [5,6]. Instead, they reach the colon where they are 
extensively metabolized by gut microbiota to colonic-derived metabolites, which are 
implicated with a vast array of biological effects [7,8]. Given considerable inter-
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individual variability in microflora, and different phenotypes being observed with 
“metabolite-producers and non-producers” after consumption of many polyphenol 
subclasses, including ellagitannins [9]. Further investigations into understanding the 
biological effects of these colonic metabolites are necessary. 
 
The pomegranate (Punica granatum L.) fruit is a rich source of ellagitannins, primarily 
punicalagin (PA) and its hydrolysis product, ellagic acid (EA) [10]. Pomegranate juice 
and extracts have been reported to show neuroprotective effects against AD 
pathogenesis in several transgenic animal models but the bioactive compound/s 
responsible have not been characterized [11−14]. Furthermore, the identity of the brain 
absorbable compounds, whether they are the natural ellagitannin constituents present 
in pomegranate, and/or their in vivo colonic-derived metabolites, is not known. 
 
The bioavailability and metabolism of ellagitannins in human subjects, after the 
consumption of pomegranate juice and pomegranate extracts, are well established [5-
6]. The major pomegranate ellagitannins, PA and others, are not found intact in 
circulation, but rather are hydrolyzed to release EA and then subsequently 
biotransformed by gut microbiota to yield urolithins (6H-dibenzo[b,d]pyran-6-one 
derivatives) (see Figure 1A). These urolithins and their phase-2 enzyme conjugates 
[methylated (i.e., conversion of hydroxyl to methoxyl or methyl ether), sulfated, and 
glucuronidated forms] [15] achieve physiologically relevant concentrations through 
enterohepatic recirculation and persist in vivo following the regular consumption of 
pomegranate foods [5−8]. Therefore, the poor bioavailability and extensive metabolism 
 120 
 
of pomegranate ellagitannins to urolithins suggest that these latter metabolites may be 
relevant bioactive compounds in vivo [5]. Moreover, urolithins have been reported to 
show anti-inflammatory [5], and anti-glycative and neuroprotective effects in vitro 
[16]. However, it is also possible that there are unidentified compounds, yet to be 
isolated from pomegranate, which are responsible for its neuroprotective effects. 
 
Our group has recently reported on the biological effects of an ellagitannin-enriched 
pomegranate extract (PE) in an aged AD transgenic animal model [17]. Therefore, from 
this PE, herein we sought to (1) isolate and identify its chemical constituents; (2) 
conduct in silico computational studies to evaluate whether the PE constituents and 
several urolithin analogues [urolithin A (UA) and urolithin B (UB) and their methyl 
derivatives, mUA, and mUB, respectively], can cross the blood-brain barrier (BBB); 
(3) evaluate the in vitro effects of PE, its constituents [PA, EA, and gallic acid (GA)], 
and the urolithins, on Aβ1−42 fibrillation and; (4) evaluate the in vivo ability of PE and 
the aforementioned pure compounds (constituents and urolithins) to abrogate Aβ1−42 
induced neurotoxicity and paralysis in Caenorhabditis elegans. This is the first study 
to investigate a PE, its constituents, and the urolithins, for in silico BBB penetrability 
and in vitro and in vivo anti-AD potential. 
 
Given that the PE was previously reported to show anti-AD effects in an animal model 
[17], we first sought to isolate and identify all of its constituents. Twenty-one 
compounds (see Figure 1B), predominantly ellagitannins, were identified from the PE 
(by HPLC, NMR, and mass spectral data; described in the Supporting Information). 
 121 
 
The isolates included PA, EA, and gallic acid (GA) and other compounds common to 
pomegranate [10, 18]. In addition, a new ellagitannin was isolated and assigned the 
common name of pomellatannin (1). This compound is a dehydroellagitannin acetone 
condensate, and its structure is in accordance to similar ellagitannin-acetone derivatives 
previously reported [19]. The remaining isolates 2−17 were identified based on 1H 
NMR and/or 13C NMR data and by comparison of these data to published literature 
reports as follows: punigluconin (2) [20], 6-O-galloyl-D-glucose (3) [21], gemin D (4) 
[22], hippomanin A (5) [22], praecoxin B (6) [23], pedunculagin (7) [24], 1,6-di-O-
galloyl-β-D-glucose (8) [21], gallic acid-3-O-β-D-(6′-O-galloyl)-glucopyranoside (9) 
[21], isocorilagin (10) [25], casuariin (11) [26], ellagic acid-4-O-β-D-glucopyranose 
(12) [27], 3,3′-di-O-methyl-ellagic acid-4-O-β-D-glucopyranose (13) [28], 4-O-α-L-
rhamnopyranosyl-ellagic acid (14) [29], 4-O-α-Larabinofuranosyl-ellagic acid (15) 
[30], gallocatechin (16) [31], and brevifolincarboxylic acid (17) [32]. 
 
Having obtained the structures of the natural constituents present in the PE, which were 
primarily ellagitannins, we next sought to investigate whether the isolates and their 
colonic derived microbial metabolites, namely urolithins, could potentially cross the 
BBB. Therefore, using in silico computational methods as previously reported [33], the 
21 constituents identified in PE, as well as UA, UB, mUA, and mUB, were evaluated 
for BBB penetrability. Interestingly, none of the isolates, but all of the urolithins, 
fulfilled criteria required for BBB penetration (Table 1). 
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The methyl derivatives of UA and UB (i.e., mUA and mUB) may have in vivo relevance 
since these compounds could be formed from the metabolism of UA and UB by phenol-
O-methyltransferase, a mammalian enzyme which is highly localized in the liver, and 
can transfer the methyl group of S-adenosylmethionine to phenols [34]. Indeed, mUA 
has previously been detected in tissues of mice after oral delivery of UA [35]. However, 
apart from these methyl derivatives, we also evaluated other potential mammalian 
enzyme-biotransformation products, namely, sulfated and glucuronidated derivatives 
of UA and UB for BBB penetrability. Interestingly, while none of these latter 
metabolites fulfilled criteria required for BBB penetration, the dimethyl derivative of 
UA (3, 8-dimethoxy-6H-dibenzo[b,d]pyran-6-one) did fulfill the criteria required for 
BBB penetration (data not shown). Therefore, it is possible that the increased 
lipophilicity caused by methylation of the hydroxyl group/s on UA and UB (to yield 
the methyl ether/methoxyl derivatives) increases BBB penetrability unlike increased 
hydrophilicity which is imparted by sulfation or glucuronidation. Methylated 
conjugates of other polyphenols, including monomeric flavanols (catechins), have been 
reported to remain intact and persist in vivo since they are not susceptible to enzymatic 
deconjugation unlike sulfated and glucuronidated metabolites which can be 
deconjugated in vivo by sulfatases and β-glucuronidases, respectively [36]. 
 
Apart from the dietary relevance of the urolithins and their conjugates due to their 
formation from ellagitannins by colonic microbiota, their subsequent biotransformation 
by mammalian enzymes, and their persistence in vivo through enterohepatic circulation 
[5−8], they could also be explored for pharmaceutical potential given that structural 
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analogues, and accompanying SAR (structure−activity related) studies, can yield 
compounds with enhanced activity and BBB penetrability. 
 
It is necessary, though, that the in silico data reported herein be substantiated by future 
animal brain tissue disposition studies. Interestingly, a recent report (using mass 
spectroscopic methods) has detected UB in brain tissues of rats after intravenous 
delivery [37]. However, animal studies to evaluate brain deposition after repeated oral 
exposure of PE, as well as the individual urolithin analogs, is warranted. These studies 
are necessary since it has been reported that the brain bioavailability of certain 
polyphenols, such as monomeric flavanols (catechins), can increase after repeated oral 
dosing as has been observed with a polyphenol-rich grape seed extract [38]. Next, 
biophysical methods were used to evaluate the effects of PE, its constituents (PA, EA, 
and GA), and the urolithins on Aβ fibrillation. This is because elevated levels of Aβ 
fibrillation and oligomerization in brain are associated with neurotoxicity in AD and 
are characteristic hallmarks which play significant roles in both early and late stages of 
AD [39, 40]. Therefore, agents which target the formation of Aβ fibrils and oligomers 
could serve as therapeutic approaches for AD prevention and/or treatment. Aβ1−42 
fibrillation was confirmed by the ThT assay which showed a significant increase in 
fluorescence which was then correlated to binding levels of ThT to Aβ fibril content, 
β-sheet formation [40] and peptide oligomerization [39]. The PE treated samples 
reduced Aβ fibrillation by 35.9% and 76.4%, at 10 and 100 μg/mL, respectively. The 
purified PE constituents and urolithins reduced Aβ fibrillation at levels ranging 
6.5−65.4% (at 10μM) and 20.2−76.3% (at 100μM) (Figure 2). These inhibitory levels 
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were similar to those of resveratrol (37.6% at 10 μM and 74.4% at 100 μM), the well-
known grape/red wine polyphenol, which has also been previously reported to reduce 
Aβ fibrillation in vitro [41]. Therefore, the preventive abilities of the urolithins on the 
assembly of neurotoxic Aβ fibril structures may contribute to the overall 
neuroprotective effect reported for pomegranate but further studies would be required 
to confirm this. 
 
Lastly, the PE was evaluated, its purified constituents, and the urolithins (all at 10 
μg/mL), using an in vivo C. elegans model of AD. The mobility curves for the CL4176 
C. elegans strain after the Aβ1−42 induction of muscular paralysis at 25°C are shown in 
figure 3 and the mean, maximum, and median survival of the worms post heat shock 
are shown in table 2. Compared to the control worms, treatment with PE (Figure 3B) 
did not have any significant effect on the mean, maximum, or median survival/mobility 
in C. elegans post induction of Aβ1−42 induced neurotoxicity and paralysis. Treatment 
with EA (Figure 3D), UB (Figure 3F), mUA (Figure 3G), and GA (Figure 3I) did not 
have any effect on the mean or medium survival/mobility in C. elegans but significantly 
(p < 0.0001) increased the maximum survival/mobility by 10.6, 8.5, 12.6, and 16.4%, 
respectively (Table 2). Among all of the samples, only treatment with mUB (Figure 
3H) significantly (p < 0.0001) increased mean, maximum, and median 
survival/mobility in C. elegans post induction of Aβ1−42 induced neurotoxicity and 
paralysis by 5.6, 13.0, and 10.3% respectively (Table 2). Treatment with PA (Figure 
3C) and UA (Figure 3E) did not have any significant effect on the maximum or median 
survival/ mobility, but significantly (p < 0.0001) decreased the mean survival/mobility 
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in C. elegans post induction of amyloid β1−42 induced neurotoxicity and paralysis by 
5.6% (Table 2). 
 
The uptake of urolithins, specifically UA and UB, has previously been reported in 
different cell lines [42, 43], but to date, similar studies have not been conducted with 
C. elegans. Therefore, using a protocol reported for C. elegans uptake studies with the 
polyphenol, quercetin [44], wild type N2 nematodes were exposed to UA and 
subsequent liquid chromatography mass spectroscopy (LC-MS/MS) analyses revealed 
its uptake into the tissues of the worms. However, further quantitative and metabolism 
studies of urolithins in C. elegans are warranted. 
 
In summary, we isolated and identified the naturally occurring constituents present in 
a PE previously reported to have anti-AD effects in an animal model [17]. None of 
these compounds, but urolithins (gut microbial metabolites derived from ellagitannins), 
fulfilled in silico criteria required for BBB penetration. Moreover, the urolithins 
prevented β-amyloid fibrillation in vitro and methyl-urolithin B, but not PE or its 
constituents, protected C. elegans post induction of Aβ1−42 induced neurotoxicity and 
paralysis. Therefore, further studies to evaluate the neuroprotective effects of urolithins 
and their structural analogs in animal models of AD are warranted.  
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2. Experimental 
2.1 Pomegranate Extract (PE).  
The pomegranate extract (PE) used for the isolation studies is of the same lot number 
as the PE recently reported by our group to show anti-AD effects in a transgenic animal 
model [17]. The PE is a whole pomegranate fruit extract (Pomella) provided by 
Verdure Sciences (Noblesville, IN) standardized to PA (ca. 30%) and EA (2.3%). 
 
2.2 Isolation and Identification of Compounds from the PE. 
Details of the isolation and identification of the compounds are provided in the 
Supporting Information 
 
2.3 Urolithins.  
Urolithins (6H-dibenzo[b,d]pyran-6-one derivatives) including urolithin A (3,8-
dihydroxy-6H-dibenzo[b,d]pyran-6-one; UA), methyl-urolithin A (3-hydroxy-8-
methoxy-6H-dibenzo[b,d]pyran-6-one; mUA), urolithin B (8-hydroxy-6H-
dibenzo[b,d]pyran-6one; UB), and methyl-urolithin B (8-methoxy-6H-
dibenzo[b,d]pyran6-one; mUB) were synthesized in our laboratory according to 
previously reported methods [45]. Their structures were verified by NMR and mass 
spectral analyses and they are all >98% purity. 
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2.4 In Silico Computational Approach.  
Using previously reported methods [33], BBB penetrability data including brain 
transfer descriptors (Table 1) were obtained using prediction software developed by 
ACD Laboratories (Toronto, Ontario, Canada). 
 
2.5 Aβ1−42 Thioflavin T (ThT) Binding Assay. 
Thioflavin T binding assay was used to measure human Aβ1−42 fibril formation as 
reported previously [39]. Briefly, Aβ1−42 peptide was dissolved in ammonium 
hydroxide, lyophilized, and redissolved in PBS buffer to obtain a final concentration of 
50μM. Treatments included 10 or 100μg/mL of PE, and 10 or 100μM of PE 
constituents (PA, GA, and EA), urolithins (UA, UB, mUA, and mUB), and the positive 
control, resveratrol. After 10 days incubation at 37°C, 20μL of each sample was added 
to 100 μL of ThT solution (10μM) and fluorescence was measured using a Spectra Max 
M2 spectrometer (Molecular Devices, Sunnyvale, CA) at excitation and emission 
wavelengths of 450 and 483nm, respectively. To evaluate the inhibitory effects on ThT 
binding, the activity of each treatment was expressed as a percent inhibition value (% 
inhibition) relative to the negative control. Percent inhibition was calculated by [(FU 
of negative control − FU of treated solution)/ FU of negative control] × 100% based on 
arbitrary fluorescence (FU). Statistical significance was analyzed by one-way factorial 
ANOVA with Tukey−Kramer post hoc comparisons. A significance value of p < 0.05 
were set to evaluate the group difference, n = 3. 
 
 
 128 
 
2.6 C. elegans Strains, Maintenance, and Assays.  
Transgenic C. elegans strain CL4176, developed to express human amyloid β1−42 in the 
muscle tissue in response to heat shock [46], were obtained from the Caenorhabditis 
Genetics Center (CGC) (University of Minnesota, Minneapolis, MN). Worms were 
grown and maintained at 16°C on 60mm culture plates with Nematode Growth Medium 
(NGM) (1.7% agar, 0.3% NaCl, 0.25% peptone, 1mM CaCl2, 1mM MgSO4, 5mg/L 
cholesterol, 2.5mM KPO4 at 16−20°C). Media was poured aseptically into culture 
plates (10mL for 60mm) using a peristaltic pump and allowed to solidify for 36h. NGM 
culture plates were then inoculated with 50 μL of Escherichia coli OP50 (CGC, 
University of Minnesota, Minneapolis, MN) overnight cultures and incubated for 8h at 
37°C. Strains of C. elegans were maintained by picking 2−3 young adult worms onto 
freshly inoculated NGM plates every 4−7 days. 
 
2.7 Age Synchronization of C. elegans. 
Prior to the beginning of the experiment, C. elegans were age synchronized as 
previously described [47, 48]. Briefly, 10 worms at L4 stage (F0) were transferred to 
single NGM plates and incubated at 16°C until they progressed to adulthood and laid 
eggs. Adults were immediately removed from the plates and the eggs were allowed to 
hatch (F1) and grow to L4 at 16°C. L4 worms of the F1 generation were again 
transferred to fresh NGM plates and allowed to mature into gravid adults and lay eggs 
at 16°C. Adults were quickly removed from the plates and returned to a 16 °C incubator 
to facilitate egg hatching. L1 worms (F2 generation) were collected from the plate by 
washing with S-basal buffer (0.59% NaCl, 5% 1M KPO4, 5mg/mL cholesterol in 
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ethanol) into a sterile 15mL centrifuge tube. Worms from a minimum of five plates 
were pooled into a single centrifuge tube and centrifuged at 8000rpm for 10min at 
10°C. The supernatant was carefully aspirated and the worms were washed again in S-
basal buffer, centrifuged, and aspirated to leave approximately 1mL of S-basal buffer 
in the centrifuge tube. The tube was gently agitated to disperse the worms and 20μL 
was pipetted onto a slide and the number of worms was counted under a stereo 
microscope. The concentration of the worms was adjusted to 10−15 worms by diluting 
with S-complete liquid media (97.7% S-basal, 1% potassium citrate, 1% trace metals, 
0.3% CaCl2, 0.3% MgSO4). A 100mg/mL suspension of E. coli OP50 was prepared by 
centrifuging 100mL of an overnight E. coli OP50 culture in LB broth at 3500rpm. Spent 
LB broth was aspirated and pellet was washed several times by resuspension and 
centrifugation in sterile distilled water. The weight of the resultant pellet was 
determined and adjusted to 100mg/mL using S-complete medium. 
 
2.8 AD Assay and Treatments in Transgenic C. elegans.  
Prior to the beginning of the experiment, C. elegans were age synchronized at 16°C 
and L1 worms from the F2 generation were transferred to control or treatment plates 
and allowed to mature gravid adult stage to lay eggs. For C. elegans treatment, stock 
solutions (1mg/mL) of the samples were prepared as follows: PE and PA were 
dissolved in a 1:1 (v/v) mixture of S-basal buffer and methanol and diluted in S-basal 
buffer to a final concentration of 1mg/mL. EA, UA, UB, mUA, and mUB were 
dissolved in DMSO and diluted in S-basal buffer to a final concentration of 1 mg/mL. 
GA was dissolved in methanol and diluted in S-basal buffer to a final concentration of 
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1mg/mL. For preparing the treatment plates, stock solutions of PE, PA, EA, GA, UA, 
UB, mUA, and mUB were added directly to the NGM media to obtain a final 
concentration of 10μg/mL. A test concentration of 10 μg/mL (i.e., 10ppm) was selected 
for these assays since the test samples included an extract (i.e., PE) along with pure 
compounds. However, for the pure compounds, the 10μg/mL concentration is 
equivalent to the following μM concentrations: PA = 9.2μM; EA = 33.1μM, GA 
=58.8μM, UA = 43.8μM, mUA = 41.3μM, UB = 47.2μM, and mUB = 44.2μM. Control 
and treatment NGM plates were then inoculated with 25μL of Escherichia coli (E. coli) 
OP50 suspension (100mg/mL) and incubated for 24h at 23°C. The OP50 used for 
inoculation of treatment plates also contained the different treatments at a final 
concentration of 10μg/mL. To standardize the food supply, the plates were then 
incubated under UV light in a Stratagene UV Stratalinker 2400 (La Jolla, CA) at 
maximum dose for 5 min to arrest growth of the E. coli OP50. Upon development of 
the eggs to the L3 stage, the incubation temperature of the plates was increased from 
16 to 25°C, in order to induce the expression of amyloid β1−42 [46]. Mobility scoring 
was conducted beginning 20h after temperature upshift and continued in 2 h increments 
until all of the worms were paralyzed. Three replicates per experiment were performed 
with a minimum of 200 worms. Failure to respond to touch (prodding with a worm 
pick) and absence of pharyngeal pumping were used to score paralyzed/dead worms. 
Survival curves were plotted to calculate the mean, median, and maximum survival of 
post heat shock treatment. 
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2.9 Statistical Analyses.  
Results are expressed as mean ± standard deviation. For the AD assay, the 
Kaplan−Meier method was used to compare the lifespan survival curves and the 
survival differences were tested for significance (p < 0.05) using the Log rank test 
(Mantel Cox). Both tests used GraphPad Prism software 6.0 (GraphPad Software, Inc., 
San Diego, CA). 
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Table 1. BBB Penetrability of Compounds Present in the PE and Urolithins (UA, UB, 
mUA, and mUB) Using Computational Methods and Software Developed by ACD/Labs 
(Toronto, Ontario, Canada) 
 
compd log P pKa fraction unbound 
in plasma 
penetration rate 
(log PS) 
penetration 
extent (log BB) 
sufficient 
BBB 
penetration 
1 −0.88 6.10 0.64 −8.10 −2.00 no 
2 0.76 1.90 0.27 −8.20 −2.00 no 
3 −1.26 7.80 0.76 −5.00 −2.00 no 
4 0.56 6.10 0.52 −6.90 −2.00 no 
5 0.67 6.10 0.41 −6.80 −2.00 no 
6 1.82 6.10 0.36 −7.10 −2.00 no 
7 1.64 5.80 0.34 −7.40 −2.00 no 
8 −0.33 7.50 0.71 −5.50 −2.00 no 
9 −0.07 4.30 0.22 −6.60 −2.00 no 
10 0.80 6.10 0.53 −6.70 −2.00 no 
11 0.60 5.80 0.46 −8.10 −2.00 no 
12 −0.08 7.00 0.49 −4.70 −0.27 no 
13 −0.58 6.60 0.38 −5.80 −2.00 no 
14 −0.10 6.60 0.30 −5.20 −2.00 no 
15 0.80 6.60 0.57 −5.10 −2.00 no 
16 0.27 8.70 0.30 −3.60 −0.42 no 
17 0.14 3.50 0.40 −4.90 −0.41 no 
punicagalin 3.20 5.70 0.07 −8.30 −2.00 no 
punicalin 0.69 5.20 0.26 −8.00 −2.00 no 
ellagic acid 1.91 6.30 0.35 −3.70 −0.16 no 
gallic acid 0.65 4.30 0.17 −4.20 −0.71 no 
UA 2.87 9.00 0.09 −1.40 0.01 yes 
UB 2.98 9.10 0.08 −1.20 0.03 yes 
mUA 3.54 9.10 0.09 −1.60 0.38 yes 
mUB 3.81 None 0.02 −1.10 −0.03 yes 
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Table 2. Survival (Mean, Median, and Maximum) of (CL4176) C. elegans Worms 
Treated with PE or Pure Compounds (10μg/ mL) 20h Post Aβ1‑42 Induction of 
Muscular Paralysis at 25°Ca 
 
 survival (h) ctrl 
   concn (10 μg/mL)     
PE PA EA GA UA UB mUA mUB 
 mean 29.45 28.20 27.80* 28.30 29.94 27.80* 30.00 29.90 31.11* 
 maximum 29.47 31.70 31.10 32.60* 34.35* 29.50 32.00* 33.02* 33.33* 
 median 29.00 28.00 28.00 28.00 30.00 28.00 30.00 30.00 32.00* 
 
a*Note: p < 0.05 log rank test (Mantel Cox).  
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Figure 1. (A) Chemical structures of punicalagin (PA) and ellagic acid (EA) and their 
gut microbial metabolites, urolithins. (B) Chemical structures of compounds 
identified in the pomegranate extract (PE). 
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Figure 2. Inhibition on Aβ1−42 fibrillation measured by the ThT binding assay. 
Treatments include 10 and 100μM of PE constituents (PA, EA, and GA), urolithins 
(UA, UB, mUA, and mUB), and the positive control, resveratrol (Resv). The 
inhibition level on ThT binding of each treated solution was expressed as a percent 
inhibition value (% inhibition) relative to the negative control. % inhibition was 
calculated based on arbitrary fluorescence (FU) using the following equation: % 
inhibition = [(FU of negative control − FU of treated solution)/FU of negative 
control] × 100%. Data was obtained from triplicate experiments (n = 3). 
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Figure 3. Mobility curves of transgenic (CL4176) C. elegans 20 h post Aβ1−42 induction 
of muscular paralysis at 25 °C. Kaplan−Meier mobility plots of C. elegans worms fed 
on (A) control [NGM]; (B) PE [NGM + 10μg/mL PE; pomella extract]; (C) PA [NGM 
+ 10μg/mL punicalagin]; (D) EA [NGM + 10μg/mL ellagic acid]; (E) UA [NGM + 
10μg/mL urolithin A]; (F) UB [NGM + 10μg/mL urolithin B]; (G) mUA [NGM + 
10μg/ mL methyl-urolithin A]; (H) mUB [NGM + 10μg/mL methyl-urolithin B]; and 
(I) GA [NGM + 10μg/mL gallic acid]. 
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Synthesis of Urolithins 
The synthesis of urolithin A was completed as the literature dictated [45] (Scheme 1).  
Briefly, 2-bromo-5-methoxybenzoic acid (1, 2.00g), was brought to reflux in basic 
(NaOH) water (15ml, pH 13.). Resorcinol (2, 5.00g) was added to the reaction and 
reflux continued for 30 minutes. Aqueous CuSO4 (5% w/v, 1.80ml) was then added 
and the solution was refluxed for an additional 10 minutes. During this addition, 8-O-
methylurolithin A (3) began to lightly precipitate out as a light yellow/white solid. The 
resulting slurry was extracted with ethyl acetate (3 x 25mL). The combined organic 
layers were then washed with a saturated brine solution, and then dried over sodium 
sulfate. The solution was filtered and solvent was removed in vacuo. The resultant 
product was washed with cold methanol to remove any leftover starting materials and 
afforded pure 8-O-methylurolithin A (Figure 1). 8-O-methylurolithin A (3, 0.040g) was 
dissolved in 0.5ml anhydrous dichloromethane and 1M BBr3 in dichloromethane 
(700uL) was added over several minutes. After 18 hours, the reaction was quenched 
through dropwise addition of distilled water.  The resultant slurry was extracted with 
ethyl acetate (3 x 25mL). The combined organic layers were then washed with a 
saturated brine solution, and then dried over sodium sulfate. The solution was filtered 
and solvent was removed in vacuo to afford urolithin A (Figure 2).   
 
Urolithin B (5) was synthesized similarly to 8-O-methylurolithin A, with slight 
modifications in the starting materials (Scheme 2).  Briefly, urolithin B requires the 
starting material 2-bromobenzoic acid (6), instead of 2-bromo-5-methoxybenzoic acid 
(1), however the reaction was carried out in the same manner.  Urolithin B was isolated 
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using silica gel column chromatography using an isocratic solvent system of 25:75 
ethyl acetate:hexanes. Once urolithin B was synthesized and isolated (Figure 3), 
successful methylation of the phenol was achieved using excess methyliodide and 
lithium bicarbonate at room temperature in dimethylformamide to produce methyl-
urolithin B (3-methoxy-6H-dibenzo[b,d]pyran-6-one) (7) (Scheme 2). The resultant 
product was washed with cold methanol to remove any leftover starting materials and 
afforded pure methyl-urolithin B (Figure 4). 
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UFLC-MS/MS optimization  
 
Metabolite identification using UFLC-MS/MS was measured using a Shimadzu UFLC 
system (3 LC-20AD pumps, Degasser DGU-20A5R, autosampler SIL-20AC HT, 
column oven CTO-20AC, Analyst v1.6.2) coupled to an ABSCIEX QTrap 4500 mass 
spectrometer using an electrospray source interface. Identification and separation was 
achieved on a reverse phase Phenomenex C18 column (250 × 4.6mm, 5m) operating 
at 40°C. The mobile phases were water:formic acid (99.9:0.1 v/v; phase A) and 
methanol:formic acid (99.9:0.1 v/v; phase B). Gradient program was as follows: 0–
20min, 50-100% B; 20–25min, 100% B; 25–27min, 100–50% B, 27– 32min, 50% B. 
Using the synthesized standards, optimization of the MS/MS fragmentation of the 
urolithins was possible.  Urolithin A was optimized over each of the specific 5 
transitions: [M+H] 229-195, 229-157, 229-139, 229-128, 229-114.9.  Each of the 
transitions is represented by a specific color: 195 blue, 157 red, 139 green, 128 grey, 
114.9 pale blue (Figure 5).   
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Uptake of Urolithin A by C. elegans 
 
 A confluent plate of wild type N2 nematodes grown in NGM/OP50 (1.7%Agar, 
0.3% NaCl, 0.25% Peptone, 1mM CaCl2, 1mM MgSO4, 5mg/L cholesterol, 2.5mM 
KPO4) (100L of overnight OP50 E. coli culture) were washed from the plate with two 
washes of 5mL of S-Basal buffer (0.59% NaCl, 5% KPO4, 5mg/ml cholesterol) and 
transferred to a 15mL centrifuge tube. Then 100L of a 50M solution of Urolithin A 
(0.05% DMSO and Water) was added to the nematodes/buffer solution. The nematodes 
were incubated at 20C for 4 hours. After incubation the nematodes were centrifuged 
at 1200 rpm for five minutes. The supernatant was decanted and the nematodes were 
washed three times with 10mL of PBS +1% BSA, 10mL of PBS + 0.01% Tween20, 
and 10mL PBS. After the final wash the supernatant was decanted and the dry pellet 
was stored at -80C.  
 
1mL of 50:49.9:0.1 (MeOH:H2O:HCl, v/v) was added to the samples and stored in -
80°C until completely frozen into a solid. Samples were removed from the freezer and 
sonicated for 15 minutes in an ice water bath, or until the sample had melted. Three 
rounds of freezing/sonication took place to ensure the rupture of the C. elegans.  
Samples were centrifuged (Eppendorf Centrifuge 5804) at 5,000rpm for 5 minutes to 
pellet worm body material and protein pieces.  The supernatant was collected and dried 
down in vacuo. 1mL of deionized water was added and the samples were sonicated for 
10 minutes. The samples were eluted through a C18 SPE (Alltech, 50mg, 1mL) column. 
Prior to the addition of the sample, the C18 SPE column was rinsed with 5mL of HPLC 
grade methanol, followed by 2mL of deionized water. 
 144 
 
 1mL of additional water was added to the column to elute a total of 2mL.  2mL of 
tetrahydrofuran (THF) was eluted through the column. The organic layer was collected 
separately and dried in vacuo.  The dried organic layer was reconstituted in 200mL of 
THF and 10uL was injected into the UFLC-MS/MS. Each of the mass transitions is 
represented by a specific color: 195 blue, 157 red, 139 green, 128 grey, 114.9 pale blue. 
Our untreated group can be found in Figure 6, while our C. elegans treated with 
urolithin A can be found in figure 7. 
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Polyphenol Microbial Metabolites 
 
In addition to ellagitannin metabolism into benzopyranone derivatives, there are other 
relationships between dietary polyphenols and bacterially metabolized endproducts 
[1-3].  It is known that the metabolites of lignans, a common dietary polyphenol 
found in flaxseed, are two smaller polyphenols enterodiol and enterolactone [2].  
Additionally it was identified in the 1940s that isoflavones, found in high 
concentrations in soy, require bacteria to be metabolized into equol [4]. Therefore, in 
addition to the development of analytical methods for the study of ellagitannins and 
urolithins, UFLC-MS/MS fragmentation to study the uptake of other polyphenol 
microbial metabolites of interest, as well as other notable dietary polyphenols, has 
been established (Table 1).  
 
[1] M. Gasperotti, S. Passamonti, F. Tramer, D. Masuero, G. Guella, F. Mattivi.  ACS 
ChemNeuro. 2015, 16, 1341-1352.  
[2] P.D. Nesbitt, Y. Lam, L.U. Am J Clin Nutr. 1999, 69, 549-555. 
[3] D. Kenneth and R. Setchell. J. of Nutirition. 2000, 13, 6545-6555. 
[4] T.J. Batterham, D.A. Shutt, N.K. Hart, A.W.H. Braden, H.J. Tweeddale. 
Australian J. of Ag. Res. 1971, 22, 131-138  
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Scheme 1. Synthesis of methyl-urolithin A (3-methoxy-8-hydroxybenzo[b,d]pyran-6-
one) (3) and urolithin A (3,8-dihydroxybenzo[b,d]pyran-6-one) (4) from 2-bromo-5-
methoxybenzoic acid (1) and resorcinol (2).  
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Scheme 2. Synthesis of methyl-urolithin B (8-methoxybenzo[b,d]pyran-6-one) (5) and 
urolithin B (8-hydroxybenzo[b,d]pyran-6-one) (7) from 2-bromobenzoic acid (6) and 
resorcinol (2). 
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Table 1: MS/MS fragmentation of other polyphenol microbial metabolites of interest, 
as well as other notable dietary polyphenols. MS3 designated by (*), MS4 designated 
by (+). 
Polyphenol Name Mass Transition 
Secoisolariciresinol [M+H] 363.42, 345, 295, 327*, 263*, 163*, 137+, 133* 
Enterodiol [M+H] 303.37, 285, 267*, 147+, 133+, 107+ 
Enterolactone [M+H] 299.34, 281*, 263+, 133+, 107* 
Daidzein [M+H] 255.23, 237, 227, 199*, 181*, 137 
Equol [M+H] 243.3, 149, 133, 123, 107  
Quercetin  [M+H] 303.24, 257, 229*, 165, 153, 137 
Curcumin [M+H] 369.39, 284, 253*, 245, 177, 145* 
Desmethoxycurcumin [M+H] 339.36, 255, 223*, 177, 145* 
Punicalagin [M+H] 1085.7, 106.78, 783, 765*, 621*, 603*, 557+, 303+ 
Punicalin [M+H] 783.52. 765, 603*, 557+, 303+ 
Ellagic Acid [M+H] 303.2, 285, 275, 257*, 247*, 229+, 201+ 
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Figure 2. 1H NMR of synthesized urolithin A (3,8-dihydroxybenzo[b,d]pyran-6-one). 
Data was measured in CH3OD at 500 MHz (
1H) and 125 MHz (13C). 
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Figure 3. 1H NMR of synthesized methyl-urolithin b (8-methoxybenzo[b,d]pyran-6-
one). Data was measured in CH3OD at 500 MHz (
1H) and 125 MHz (13C). 
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Figure 4. 1H NMR of synthesized urolithin b (8-hydroxybenzo[b,d]pyran-6-one). 
Data was measured in CH3OD at 500 MHz (
1H) and 125 MHz (13C). 
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Figure 5. UFLC-MS/MS transitions of the fragmentation of UA standard. Each 
transition is represented by a specific color: [M+H] 229-195 blue, 229-157 red, 229-
139 green, 229-128 grey, 229-114.9 pale blue.    
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Figure 6. UFLC-MS/MS transitions of the fragmentation of untreated worms. Each 
MS/MS transition of UA is represented by a specific color: [M+H] 229-195 blue, 229-
157 red, 229-139 green, 229-128 grey, 229-114.9 pale blue. 
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Figure 7. UFLC-MS/MS transitions of the fragmentation of worms treated with UA. 
Each MS/MS transition of UA is represented by a specific color: [M+H] 229-195 
blue, 229-157 red, 229-139 green, 229-128 grey, 229-114.9 pale blue.  
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CONCLUSIONARY REMARKS 
 
Well known medicinal chemist and text book author, Dr. Richard Silverman, describes 
medicinal chemistry in The Organic Chemistry of Drug Design and Delivery: 
“Medicinal Chemistry may involve isolation of compounds from nature 
or the synthesis of new molecules, investigations of the relationships 
between the structure of natural and/or synthetic compounds and their 
biological activates, elucidations of their interactions with receptors of 
various kinds, the determination of their absorption, transport and 
distributions properties, and studies of metabolic transformations.” 
Dr. Silverman’s lengthy description of medicinal chemistry highlights how diverse the 
studies of drug discovery, and drug development, can be during the preclinical stages.  
The work provided in this dissertation highlights several key elements of Dr. 
Silverman’s definition, including the isolation of compounds from nature, the synthesis 
of new molecules, elucidations of the interactions between receptors and their ligands, 
and studies of metabolic transformations.   
 
The phytochemical investigation of Carex vulpinoidea (Fox Sedge) in pursuit of novel 
stilbenes concluded with the identification and structural elucidation of two new 
monomeric stilbenes, namely, vulpinoideols A and B.  A synthetic route for naturally 
isolated gallotannins, namely, maplexins F and J, previously isolated from red maple 
(Acer rubrum) tree bark, was developed.  Additionally, the ligand-enzyme interaction 
between the gallotannins and their target enzyme, α-glucosidase, was evaluated using 
biophsyical tools. Finally, a synthetic route was also developed for the ellagitannin gut-
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microbial metabolites, urolithins (dibenzopyranone derivatives), along with analytical 
UFLC-MS/MS methods to study the cellular and tissue uptake of the urolithins, as well 
as other dietary polyphenolic metabolites of interest. 
 
While today’s pharmaceuticals trend towards increasing the generation and 
administration of larger macromolecules, straying from the traditional small molecules, 
I believe that there will continue to be a demand for novel small molecule driven 
research.  Traditionally, the research has been motivated by a single compound driving 
a single biological response, however I believe the future momumental discoveries of 
small molecules and natural products will involve the complex interactions and 
diversity of compounds found in botanical extracts. Even now while conclusive data 
on the effectiveness, pharmacological, and toxicological data is difficult to identify, 
dietary polyphenols continue to attract both media and research attention.  Additionally, 
we are only just beginning to scratch the surface of knowledge into the gut microbiota.  
In the future lies extensive analytical and instrumental advances, which will allow us 
to tease apart the complex biochemical relationships, and their metabolisms.   
R.B. Silverman and M.W. Holladay. The organic chemistry of drug design and drug 
delivery. Elsevier Inc, San Diego California, USA. 2014. 
 
 
 
 
 
